<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1293" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1293/" /><meta name="ncbi_pagename" content="Cerebral Cavernous Malformation, Familial - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Cerebral Cavernous Malformation, Familial - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Cerebral Cavernous Malformation, Familial" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/08/04" /><meta name="citation_author" content="Leslie Morrison" /><meta name="citation_author" content="Amy Akers" /><meta name="citation_pmid" content="20301470" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1293/" /><meta name="citation_keywords" content="Familial Cavernous Hemangioma" /><meta name="citation_keywords" content="Familial Cerebral Cavernous Angioma" /><meta name="citation_keywords" content="Familial Cerebral Cavernous Malformation" /><meta name="citation_keywords" content="Familial Cavernous Hemangioma" /><meta name="citation_keywords" content="Familial Cerebral Cavernous Angioma" /><meta name="citation_keywords" content="Familial Cerebral Cavernous Malformation" /><meta name="citation_keywords" content="Cerebral cavernous malformations 2 protein" /><meta name="citation_keywords" content="Krev interaction trapped protein 1" /><meta name="citation_keywords" content="Programmed cell death protein 10" /><meta name="citation_keywords" content="CCM2" /><meta name="citation_keywords" content="KRIT1" /><meta name="citation_keywords" content="PDCD10" /><meta name="citation_keywords" content="Cerebral Cavernous Malformation, Familial" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cerebral Cavernous Malformation, Familial" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Leslie Morrison" /><meta name="DC.Contributor" content="Amy Akers" /><meta name="DC.Date" content="2016/08/04" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1293/" /><meta name="description" content="Cerebral cavernous malformations (CCMs) are vascular malformations in the brain and spinal cord comprising closely clustered, enlarged capillary channels (caverns) with a single layer of endothelium without mature vessel wall elements or normal intervening brain parenchyma. The diameter of CCMs ranges from a few millimeters to several centimeters. CCMs increase or decrease in size and increase in number over time. Hundreds of lesions may be identified, depending on the person's age and the quality and type of brain imaging used. Although CCMs have been reported in infants and children, the majority become evident between the second and fifth decades with findings such as seizures, focal neurologic deficits, nonspecific headaches, and cerebral hemorrhage. Up to 50% of individuals with FCCM remain symptom free throughout their lives. Cutaneous vascular lesions are found in 9% of those with familial cerebral cavernous malformations (FCCM; see Diagnosis/testing) and retinal vascular lesions in almost 5%." /><meta name="og:title" content="Cerebral Cavernous Malformation, Familial" /><meta name="og:type" content="book" /><meta name="og:description" content="Cerebral cavernous malformations (CCMs) are vascular malformations in the brain and spinal cord comprising closely clustered, enlarged capillary channels (caverns) with a single layer of endothelium without mature vessel wall elements or normal intervening brain parenchyma. The diameter of CCMs ranges from a few millimeters to several centimeters. CCMs increase or decrease in size and increase in number over time. Hundreds of lesions may be identified, depending on the person's age and the quality and type of brain imaging used. Although CCMs have been reported in infants and children, the majority become evident between the second and fifth decades with findings such as seizures, focal neurologic deficits, nonspecific headaches, and cerebral hemorrhage. Up to 50% of individuals with FCCM remain symptom free throughout their lives. Cutaneous vascular lesions are found in 9% of those with familial cerebral cavernous malformations (FCCM; see Diagnosis/testing) and retinal vascular lesions in almost 5%." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1293/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ccm/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1293/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89283FDFC733A1000000000A540523.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1293_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1293_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cco/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ctx/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1293_"><span class="title" itemprop="name">Cerebral Cavernous Malformation, Familial</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial Cavernous Hemangioma, Familial Cerebral Cavernous Angioma, Familial Cerebral Cavernous Malformation</div><p class="contrib-group"><span itemprop="author">Leslie Morrison</span>, MD and <span itemprop="author">Amy Akers</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1293_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1293_ai__"><div class="contrib half_rhythm"><span itemprop="author">Leslie Morrison</span>, MD<div class="affiliation small">Departments of Neurology and Pediatrics<br />University of New Mexico<br />Albuquerque, New Mexico<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mnu.dulas@nosirroml" class="oemail">ude.mnu.dulas@nosirroml</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amy Akers</span>, PhD<div class="affiliation small">Angioma Alliance<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.amoigna@sreka.yma" class="oemail">gro.amoigna@sreka.yma</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 24, 2003</span>; Last Update: <span itemprop="dateModified">August 4, 2016</span>.</p><p><em>Estimated reading time: 34 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ccm.Summary" itemprop="description"><h2 id="_ccm_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Cerebral cavernous malformations (CCMs) are vascular malformations in the brain and spinal cord comprising closely clustered, enlarged capillary channels (caverns) with a single layer of endothelium without mature vessel wall elements or normal intervening brain parenchyma. The diameter of CCMs ranges from a few millimeters to several centimeters. CCMs increase or decrease in size and increase in number over time. Hundreds of lesions may be identified, depending on the person's age and the quality and type of brain imaging used. Although CCMs have been reported in infants and children, the majority become evident between the second and fifth decades with findings such as seizures, focal neurologic deficits, nonspecific headaches, and cerebral hemorrhage. Up to 50% of individuals with FCCM remain symptom free throughout their lives. Cutaneous vascular lesions are found in 9% of those with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cerebral cavernous malformations (FCCM; see Diagnosis/testing) and retinal vascular lesions in almost 5%.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cerebral cavernous malformation (FCCM) is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>either</i>
<i>or both</i> of the following:</p><ul><li class="half_rhythm"><div>Multiple CCMs, or one CCM and at least one other family member with one or more CCMs</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i></div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Surgical removal of lesions associated with intractable seizures or focal deficits from recurrent hemorrhage or mass effect may be considered. Treatment of seizures and epilepsy is symptomatic. Headaches are managed symptomatically and prophylactically. Acute and chronic neurologic deficits may be managed through rehabilitation.</p><p><i>Surveillance:</i> Brain MRI imaging with gradient echo (GRE) or susceptibility-weighted imaging (SWI) is indicated in individuals experiencing new neurologic symptoms.</p><p><i>Agents/circumstances to avoid:</i> Agents that increase risk of hemorrhage: aspirin, NSAIDs, heparin, and sodium warfarin (Coumadin<sup>&#x000ae;</sup>). Note: When these medications are necessary for treatment of life-threatening thrombosis, careful consideration and close medical monitoring of dosage are warranted. Radiation to the central nervous system may lead to new lesion formation.</p><p><i>Evaluation of relatives at risk:</i> Asymptomatic at-risk relatives of all ages may be evaluated by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known) to allow early diagnosis and monitoring of those at high risk of developing CCMs. Symptomatic relatives may undergo brain MRI with special sequences (GRE or SWI) to determine presence, size, and location of lesions.</p><p><i>Pregnancy management:</i> Baseline MRI one year prior to delivery is recommended to determine lesion locations; pregnant women with FCCM who have had recent brain or spinal cord hemorrhage, epilepsy, or migraine require closer monitoring during pregnancy; individulas with FCCM are at a higher risk for symptomatic cerebral hemorrhage during pregnancy than those with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CCM; seizure is the most common symptom of CCM hemorrhage during pregnancy; exposure to antiepileptic medication during pregnancy may increase the risk for adverse fetal outcome but is generally recommended because the fetal risk is typically less than that associated with fetal exposure to an untreated maternal seizure disorder.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Familial CCM is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown. Each child of an individual with FCCM has a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant has been identified in the family.</p></div></div><div id="ccm.Diagnosis"><h2 id="_ccm_Diagnosis_">Diagnosis</h2><div id="ccm.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Familial cerebral cavernous malformation (FCCM) <b>should be suspected</b> in individuals with the following clinical findings, brain imaging, histopathology, and family history.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Seizure disorder with onset at any age, but most typically between the second and fifth decades</div></li><li class="half_rhythm"><div>Focal neurologic deficits</div></li><li class="half_rhythm"><div>Nonspecific headaches</div></li><li class="half_rhythm"><div>Cerebral hemorrhage</div></li><li class="half_rhythm"><div>Vascular skin lesions (capillary malformations, hyperkeratotic cutaneous capillary venous malformations, venous malformations, red macules, and/or nodular venous malformations)</div></li><li class="half_rhythm"><div>Retinal cavernomas and rare choroidal hemangiomas</div></li></ul><p><b>Brain imaging.</b> Brain MRI using either gradient echo (GRE) or susceptibility-weighted imaging (SWI) demonstrating one or more cerebral cavernous malformations [<a class="bk_pop" href="#ccm.REF.bulut.2014.5296">Bulut et al 2014</a>]:</p><ul><li class="half_rhythm"><div>The characteristic lesion is of mixed signal intensity with a central reticulated core surrounded by a dark ring, which is presumed to be hemosiderin deposition from prior hemorrhage [<a class="bk_pop" href="#ccm.REF.rigamonti.1987.518">Rigamonti et al 1987</a>] (see <a class="figpopup" href="/books/NBK1293/table/ccm.T.classification_of_ccm_by_mri_and_h/?report=objectonly" target="object" rid-figpopup="figccmTclassificationofccmbymriandh" rid-ob="figobccmTclassificationofccmbymriandh">Table 2</a>).</div></li><li class="half_rhythm"><div>Lesions may appear as black dots, mixed signal intensity, or with rims of hemosiderin, fresh hemorrhage, or edema [<a class="bk_pop" href="#ccm.REF.alshahi_salman.2008.3222">Al-Shahi Salman et al 2008</a>, <a class="bk_pop" href="#ccm.REF.de_souza.2008.154">de Souza et al 2008</a>, <a class="bk_pop" href="#ccm.REF.nikoubashman.2013.e453">Nikoubashman et al 2013</a>, <a class="bk_pop" href="#ccm.REF.nikoubashman.2015.2177">Nikoubashman et al 2015</a>].</div></li></ul><p>Note: Intravenous gadolinium contrast administration is not needed for identification of cavernous malformations, but is useful in identifying complex vascular malformations with arterial and venous components (which on rare occasion are associated with CCMs) and other types of vascular brain malformations including telangiectasias, arteriovenous malformations, and aneurysms.</p><p><b>Histopathology</b></p><ul><li class="half_rhythm"><div>Closely clustered enlarged capillary channels (caverns) ranging from two to 55 mm (mean: 8 mm) with a single layer of endothelium without normal mature vessel wall elements or intervening brain parenchyma</div></li><li class="half_rhythm"><div>Thrombosis and intra- and extralesional hemorrhage. Edema may surround lesions with recent hemorrhage.</div></li></ul><p><b>Family history.</b> Two or more family members (including the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>) with cerebral cavernous malformations (CCM). Note: Individuals with a single CCM may have <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM; therefore, the presence of a single CCM in an individual with no family history of CCM (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case) does not exclude the diagnosis of familial CCM (FCCM).</p></div><div id="ccm.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cerebral cavernous malformation (FCCM) <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>either</i>
<i>or both</i> of the following:</p><ul><li class="half_rhythm"><div>Multiple CCMs, or one CCM and at least one other family member with one or more CCMs</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1293/table/ccm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figccmTmoleculargenetictestingusedin" rid-ob="figobccmTmoleculargenetictestingusedin">Table 1</a>)</div></li></ul><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>KRIT1</i>, <i>CCM2</i>, and <i>PDCD10</i> is performed first (either sequentially or concurrently) followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><p>Several founder pathogenic variants that are useful for stratifying genetic testing in specific populations have been identified:</p><ul><li class="half_rhythm"><div>In individuals with ancestry from northern Mexico and the American Southwest, the pathogenic <a class="figpopup" href="/books/NBK1293/table/ccm.T.krit1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figccmTkrit1pathogenicvariantsdiscusse" rid-ob="figobccmTkrit1pathogenicvariantsdiscusse">p.Gln455Ter</a> variant in <i>KRIT1</i> is common.</div></li><li class="half_rhythm"><div>Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> for the <i>CCM2</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2-10 deletion may be performed as part of the first tier of the testing strategy in individuals from the US, where up to 22% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals will have this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ccm.REF.liquori.2007.69">Liquori et al 2007</a>, <a class="bk_pop" href="#ccm.REF.stahl.2008.709">Stahl et al 2008</a>].</div></li><li class="half_rhythm"><div>In individuals of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> descent a recurrent <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CCM2,</i>
<a class="figpopup" href="/books/NBK1293/table/ccm.T.ccm2_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figccmTccm2pathogenicvariantsdiscussed" rid-ob="figobccmTccm2pathogenicvariantsdiscussed">c.30+5_30+6delGCinsTT</a>, has been identified in multiple unrelated kindreds [<a class="bk_pop" href="#ccm.REF.gallione.2011.662">Gallione et al 2011</a>].</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>KRIT1</i>, <i>CCM2</i>, and <i>PDCD10</i> and other genes of interest (see <a href="#ccm.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="ccm.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Familial Cerebral Cavernous Malformation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of FCCM Attributed to Pathogenic Variants in This Gene&#x000a0;<sup>2</sup></th><th id="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>3</sup> Detected by Test Method</th></tr><tr><th headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRIT1</i></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">53%-65%</td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%-95%&#x000a0;<sup>6</sup></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-15%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CCM2</i></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%-70%&#x000a0;<sup>6</sup></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%-60%&#x000a0;<sup>6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PDCD10</i></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-16%</td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-90%&#x000a0;<sup>6</sup></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%-10%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_ccm.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ccm.TF.1.1"><p class="no_margin">See <a href="/books/NBK1293/#ccm.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ccm.TF.1.2"><p class="no_margin">Following stringent inclusion criteria for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM (multiple lesions and/or family history), a causative <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in either <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> is detected in at least 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families [<a class="bk_pop" href="#ccm.REF.denier.2006.550">Denier et al 2006</a>, <a class="bk_pop" href="#ccm.REF.liquori.2007.69">Liquori et al 2007</a>, <a class="bk_pop" href="#ccm.REF.dangelo.2011.215">D'Angelo et al 2011</a>, <a class="bk_pop" href="#ccm.REF.riant.2013.165">Riant et al 2013</a>, <a class="bk_pop" href="#ccm.REF.spiegler.2014.176">Spiegler et al 2014</a>], with some authors reporting 97% detection rates [<a class="bk_pop" href="#ccm.REF.cigoli.2014.e110438">Cigoli et al 2014</a>].</p></div></dd><dt>3. </dt><dd><div id="ccm.TF.1.3"><p class="no_margin">See <a href="#ccm.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="ccm.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="ccm.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ccm.TF.1.6"><p class="no_margin">Pathogenic alleles detected by <a class="bk_pop" href="#ccm.REF.riant.2013.165">Riant et al [2013]</a> by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and methodology: <i>KRIT</i>: 68/80 alleles by sequencing and 12/80 alleles by del/dup; <i>CCM2:</i> 16/23 alleles by sequencing and 7/23 alleles by del/dup; <i>PDCD10:</i> 16/19 by sequencing and 3/19 alleles by del/dup. Pathogenic alleles detected by <a class="bk_pop" href="#ccm.REF.liquori.2007.69">Liquori et al [2007]</a> by gene and methodology: <i>KRIT</i>: 23/24 alleles by sequencing and 1/24 alleles by del/dup; <i>CCM2:</i> 10/24 alleles by sequencing and 14/24 alleles by del/dup; <i>PDCD10:</i> 4/4 by sequencing and 0/24 alleles by del/dup.</p></div></dd><dt>7. </dt><dd><div id="ccm.TF.1.7"><p class="no_margin">Variability in the detection rate of <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing results from the high prevalence of a founder <i>CCM2</i> deletion (exons 2-10) in the US. This deletion was rare in an Italian population [<a class="bk_pop" href="#ccm.REF.liquori.2007.69">Liquori et al 2007</a>, <a class="bk_pop" href="#ccm.REF.liquori.2008.25">Liquori et al 2008</a>].</p></div></dd><dt>8. </dt><dd><div id="ccm.TF.1.8"><p class="no_margin">Based on exclusion of a <i>PDCD10</i> (CCM3 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a large family whose <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is linked to the CCM3 locus but not to the CCM1 (<i>KRIT1</i>) or CCM2 (<i>CCM2</i>) loci, <a class="bk_pop" href="#ccm.REF.liquori.2006.118">Liquori et al [2006]</a> proposed a putative CCM4 locus at 3q26.3-q27.2. However, with high rates of pathogenic variant detection in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals the existence of a CCM4 locus is unlikely.</p></div></dd></dl></div></div></div></div></div><div id="ccm.Clinical_Characteristics"><h2 id="_ccm_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ccm.Clinical_Description"><h3>Clinical Description</h3><p><b>Neurologic findings.</b> In <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM, up to 50% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in either <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> are clinically asymptomatic, although at least half of these individuals have identifiable CCM lesions on head imaging [<a class="bk_pop" href="#ccm.REF.battistini.2007.843">Battistini et al 2007</a>, <a class="bk_pop" href="#ccm.REF.fischer.2013.302">Fischer et al 2013</a>]. However, based on CCMs ascertained on autopsy, approximately 90% of individuals with either <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CCM or FCCM were asymptomatic [<a class="bk_pop" href="#ccm.REF.otten.1989.82">Otten et al 1989</a>].</p><p>Cerebral cavernous malformation (CCM) has been reported in infants and children, but the majority of individuals with FCCM present with symptoms between the second and fifth decades. In one study, 9% of individuals were symptomatic before age ten years, 62%-72% between ages ten and 40 years, and 19% after age 40 years [<a class="bk_pop" href="#ccm.REF.gunel.1996.946">Gunel et al 1996</a>]. A more recent study of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals found that 20% were younger than age ten years and 33% younger than age 18 years at the time of referral for genetic testing; the age of symptom onset was not cited [<a class="bk_pop" href="#ccm.REF.spiegler.2014.176">Spiegler et al 2014</a>].</p><p>Clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals most often present with seizures (40%-70%), focal neurologic deficits (35%-50%), nonspecific headaches (10%-30%), and cerebral hemorrhage (32%) [<a class="bk_pop" href="#ccm.REF.denier.2004b.213">Denier et al 2004b</a>]. Five percent of individuals with intractable temporal lobe epilepsy have CCM [<a class="bk_pop" href="#ccm.REF.spencer.1984.432">Spencer et al 1984</a>], although it is unknown how many of these individuals have FCCM.</p><p>Central nervous system hemorrhages may be intralesional or extend beyond the lesion [<a class="bk_pop" href="#ccm.REF.alshahi_salman.2008.3222">Al-Shahi Salman et al 2008</a>]. In children, hemorrhage and an aggressive presentation were thought to be more likely than in adults [<a class="bk_pop" href="#ccm.REF.lee.2008.321">Lee et al 2008</a>]; however, <a class="bk_pop" href="#ccm.REF.alholou.2012.198">Al-Holou et al [2012]</a> evaluated hemorrhage risk in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals younger than age 25 years and found that it was similar to the rates in adults. In general, symptom onset in children with FCCM is earlier than in children with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> (i.e., non-genetic) CCM [<a class="bk_pop" href="#ccm.REF.acciarri.2009.81">Acciarri et al 2009</a>].</p><p>Cavernous malformation can lead to death from intracranial hemorrhage or from complications of surgery [<a class="bk_pop" href="#ccm.REF.acciarri.2009.81">Acciarri et al 2009</a>] particularly when found in the brain stem [<a class="bk_pop" href="#ccm.REF.bhardwaj.2009.458">Bhardwaj et al 2009</a>, <a class="bk_pop" href="#ccm.REF.abla.2010.1589">Abla et al 2010</a>]. Of note, severe hemorrhage from CCM is less common than hemorrhage from arteriovenous malformations (AVM) [<a class="bk_pop" href="#ccm.REF.selman.2000">Selman et al 2000</a>].</p><p><b>Brain MRI.</b> Either gradient echo (GRE) or susceptibility-weighted imaging (SWI) is the imaging modality of choice. While larger, complex lesions are visible on routine T<sub>1</sub>- and T<sub>2</sub>- weighted MRI sequences, GRE MRI sequences reveal up to triple the number of lesions and SWI MRI sequences reveal an additional doubling or tripling [<a class="bk_pop" href="#ccm.REF.cooper.2008.382">Cooper et al 2008</a>, <a class="bk_pop" href="#ccm.REF.de_souza.2008.154">de Souza et al 2008</a>]. Use of these sensitive imaging techniques may reveal hundreds of lesions [<a class="bk_pop" href="#ccm.REF.petersen.2010.377">Petersen et al 2010</a>].</p><p>Four characteristic types of lesions have been described [<a class="bk_pop" href="#ccm.REF.zabramski.1994.422">Zabramski et al 1994</a>] by MRI and histology (see <a class="figpopup" href="/books/NBK1293/table/ccm.T.classification_of_ccm_by_mri_and_h/?report=objectonly" target="object" rid-figpopup="figccmTclassificationofccmbymriandh" rid-ob="figobccmTclassificationofccmbymriandh">Table 2</a>). Dividing CCM into these radiologic and histologic types is clinically useful in predicting hemorrhage risk [<a class="bk_pop" href="#ccm.REF.nikoubashman.2015.2177">Nikoubashman et al 2015</a>].</p><div id="ccm.T.classification_of_ccm_by_mri_and_h" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Classification of CCM by MRI and Histopathology</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.T.classification_of_ccm_by_mri_and_h/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.T.classification_of_ccm_by_mri_and_h_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lesion</th><th id="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MR Signal</th><th id="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Histopathology</th><th id="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Correlation</th></tr></thead><tbody><tr><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Type&#x000a0;1</b></td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>SE T<sub>1</sub>: hyperintense core</div></li><li class="half_rhythm"><div>SE T<sub>2</sub>: hyperintense core or hypointense core</div></li></ul>
</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Subacute hemorrhage</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute hemorrhage; high frequency of bleeding relapse</td></tr><tr><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Type&#x000a0;2</b></td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>SE T<sub>1</sub>: reticulated mixed signal core</div></li><li class="half_rhythm"><div>SE T<sub>2</sub>: reticulated mixed signal core w/surrounding hypointense rim</div></li></ul>
</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lesions w/hemorrhages &#x00026; thromboses of varying ages</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Type&#x000a0;3</b></td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>SE T<sub>1</sub>: iso- or hypointensity</div></li><li class="half_rhythm"><div>SE T<sub>2</sub>: hypointense lesion w/hypointense rim magnifying size of lesion</div></li></ul>
</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic hemorrhage w/hemosiderin staining in &#x00026; around lesion</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Type&#x000a0;4</b></td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>SE T<sub>1</sub>: not seen</div></li><li class="half_rhythm"><div>SE T<sub>2</sub>: not seen</div></li><li class="half_rhythm"><div>GRE: punctate hypointense lesion</div></li><li class="half_rhythm"><div>SWI: punctuate hypointense lesion</div></li></ul>
</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tiny CCM or telangiectasia</td><td headers="hd_h_ccm.T.classification_of_ccm_by_mri_and_h_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Possibly represent true new lesions</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#ccm.REF.zabramski.1994.422">Zabramski et al [1994]</a>, <a class="bk_pop" href="#ccm.REF.de_souza.2008.154">de Souza et al [2008]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">Specific MRI sequences and programs: GRE = gradient echo MRI; SE = spin echo MRI; SWI = susceptibility-weighted imaging MRI</p></div></dd></dl></div></div></div><p>The medical significance of small lesions (classified as type 4) seen on MRI (sometimes referred to as cerebral dot-like cavernomas or black spot lesions) is unclear. For these lesions, a mean bleeding rate of 0.7% per lesion&#x02013;year was found over a period of 5.5 years in 18 children with either an inherited or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i> or <i>PDCD10</i>. Of the ten inidividuals who had hemorrhages, only two were symptomatic [<a class="bk_pop" href="#ccm.REF.nikoubashman.2013.e453">Nikoubashman et al 2013</a>, <a class="bk_pop" href="#ccm.REF.nikoubashman.2015.2177">Nikoubashman et al 2015</a>].</p><p>FCCM is a dynamic disease on neuroimaging studies. <a class="bk_pop" href="#ccm.REF.brunereau.2000.475">Brunereau et al [2000]</a> and <a class="bk_pop" href="#ccm.REF.labauge.2001.1825">Labauge et al [2001]</a> determined that new lesions appear at a rate of between 0.2 and 0.4 lesions per patient-year. In both FCCM and <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CCM lesions may change in size and signal characteristics over time.</p><p>It had been assumed that individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM generally have multiple lesions while individuals who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence of a CCM in a family) have a single lesion; however, in a study of 138 individuals (62 symptomatic and 76 asymptomatic) with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRIT1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="bk_pop" href="#ccm.REF.denier.2004b.213">Denier et al [2004b]</a> found that 26 (20%) appeared to have only one lesion when evaluated with T<sub>2</sub>-weighted MRI sequences. Further examination with GRE sequence MRI of 12 of the apparently symptom-free individuals revealed multiple lesions in eight (66%) and a single detectable lesion in four (33%). Additionally, eight of the symptom-free individuals showed no lesion at all. Thus, approximately 13% of individuals with a heterozygous <i>KRIT1</i> pathogenic variant had only one lesion detected when examined with T<sub>2</sub>-weighted MRI and about 2% had only one lesion detected when examined with GRE sequence MRI. Since lesions are more readily identifiable using SWI, the number of clinically asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals is likely to increase as longitudinal studies using SWI are published.</p><p>Some studies have identified an increasing number of lesions in families by generation: five to 12 lesions in children and adolescents; 20 lesions in parents; and more than 100 lesions in grandparents [<a class="bk_pop" href="#ccm.REF.horowitz.1995.1353">Horowitz &#x00026; Kondziolka 1995</a>]. This is likely related to ascertainment bias; it has not been borne out by subsequent studies.</p><p><a class="bk_pop" href="#ccm.REF.brunereau.2000.475">Brunereau et al [2000]</a> and <a class="bk_pop" href="#ccm.REF.labauge.2001.1825">Labauge et al [2001]</a> determined that in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM 76%-86% of lesions were supratentorial and 16%-24% infratentorial. Of the infratentorial lesions, almost half occurred in the brain stem. Brain stem lesions are frequently associated with symptoms [<a class="bk_pop" href="#ccm.REF.fritschi.1994.35">Fritschi et al 1994</a>].</p><p>Spinal cord lesions are considered rare, reportedly occurring in fewer than 5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ccm.REF.deutsch.2000.65">Deutsch et al 2000</a>, <a class="bk_pop" href="#ccm.REF.badhiwala.2014.662">Badhiwala et al 2014</a>]. In one large family with a known <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRIT1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, spinal cavernous angiomas, either alone or associated with vertebral hemangiomas, were found in five of eight individuals studied using spinal MRI [<a class="bk_pop" href="#ccm.REF.toldo.2009.167">Toldo et al 2009</a>]. <a class="bk_pop" href="#ccm.REF.cohengadol.2006.376">Cohen-Gadol et al [2006]</a> found that 40% of persons presenting with a spinal CM had a similar intracranial lesion (CCM). In this same study 40% of persons with both spinal and intracranial CMs were <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases. Molecular genetic testing was not done in this study; however, multiplicity of spinal cord cavernous malformations are strongly suggestive of FCCM.</p><p><b>Other.</b> Vascular lesions found outside of the central nervous system have been reported in association with multiple intracranial cavernomas (cavernous malformations) with and without confirmed <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i>.</p><ul><li class="half_rhythm"><div><b>Vascular skin lesions</b> have been reported in 9% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i> and less commonly in individuals with a heterozygous pathogenic variant in <i>CCM2</i> or <i>PDCD10</i> [<a class="bk_pop" href="#ccm.REF.eerola.2000.1351">Eerola et al 2000</a>, <a class="bk_pop" href="#ccm.REF.zlotoff.2007.210">Zlotoff et al 2007</a>, <a class="bk_pop" href="#ccm.REF.sirvente.2009.1066">Sirvente et al 2009</a>, <a class="bk_pop" href="#ccm.REF.toldo.2009.167">Toldo et al 2009</a>, <a class="bk_pop" href="#ccm.REF.kurlemann.2012.513">Kurlemann 2012</a>, <a class="bk_pop" href="#ccm.REF.campione.2013.2">Campione et al 2013</a>, <a class="bk_pop" href="#ccm.REF.brownlee.2014.e133">Brownlee &#x00026; Roxburgh 2014</a>, <a class="bk_pop" href="#ccm.REF.cigoli.2014.e110438">Cigoli et al 2014</a>, <a class="bk_pop" href="#ccm.REF.bilo.2016.962">Bilo et al 2016</a>].</div><ul><li class="half_rhythm"><div>In the 38 individuals with FCCM and cutaneous vascular malformations reported by <a class="bk_pop" href="#ccm.REF.sirvente.2009.1066">Sirvente et al [2009]</a>, the skin lesions were classified as capillary malformations (13); hyperkeratotic cutaneous capillary venous malformation (15); venous malformations (8); and unclassified (2).</div></li><li class="half_rhythm"><div>Bluish nodules and other subcutaneous nodules have been described in the venous malformations.</div></li><li class="half_rhythm"><div>Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have skin lesions removed secondary to bleeding, pain, protrusion, concern about cosmesis, or concern for malignancy.</div></li></ul></li><li class="half_rhythm"><div><b>Retinal vascular lesions</b>, reported in 5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, may include retinal cavernomas and (rarely) choroidal hemangiomas [<a class="bk_pop" href="#ccm.REF.wood.1957.249">Wood et al 1957</a>, <a class="bk_pop" href="#ccm.REF.sarraf.2000.969">Sarraf et al 2000</a>, <a class="bk_pop" href="#ccm.REF.labauge.2006.885">Labauge et al 2006</a>].</div></li><li class="half_rhythm"><div><b>Liver cavernoma</b> have been reported in two Italian families with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CCM2</i> but have not been confirmed to occur with an increased frequency in individuals with FCCM compared to individuals in the general population [<a class="bk_pop" href="#ccm.REF.drigo.1994.205">Drigo et al 1994</a>, <a class="bk_pop" href="#ccm.REF.toldo.2009.167">Toldo et al 2009</a>].</div></li><li class="half_rhythm"><div><b>Renal angioma</b> has been reported in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual of Italian descent [<a class="bk_pop" href="#ccm.REF.battistini.2007.843">Battistini et al 2007</a>].</div></li><li class="half_rhythm"><div><b>Atrial myxoma</b> [<a class="bk_pop" href="#ccm.REF.ardeshiri.2008.11">Ardeshiri et al 2008</a>, <a class="bk_pop" href="#ccm.REF.sharma.2011.110.e1">Sharma et al 2011</a>] is rare and has not yet been definitively attributed to FCCM [<a class="bk_pop" href="#ccm.REF.dobyns.1987.578">Dobyns et al 1987</a>, <a class="bk_pop" href="#ccm.REF.drigo.1994.205">Drigo et al 1994</a>, <a class="bk_pop" href="#ccm.REF.labauge.1999.250">Labauge et al 1999</a>, <a class="bk_pop" href="#ccm.REF.eerola.2000.1351">Eerola et al 2000</a>, <a class="bk_pop" href="#ccm.REF.chen.2002.91">Chen et al 2002</a>, <a class="bk_pop" href="#ccm.REF.toldo.2009.167">Toldo et al 2009</a>, <a class="bk_pop" href="#ccm.REF.lanfranconi.2014.158">Lanfranconi et al 2014</a>].</div></li></ul></div><div id="ccm.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p>The clinical course of FCCM varies within and between families; therefore, the following are generalizations.</p><p><b><i>KRIT1.</i></b> Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i> may have a less severe clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than those with a heterozygous pathogenic variant in either <i>CCM2</i> or <i>PDCD10</i> [<a class="bk_pop" href="#ccm.REF.gault.2006.1278">Gault et al 2006</a>].</p><ul><li class="half_rhythm"><div>Up to 50% of persons with FCCM caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KRIT1</i> ultimately become symptomatic.</div></li><li class="half_rhythm"><div>Skin lesions may be more common in persons with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>KRIT1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ccm.REF.sirvente.2009.1066">Sirvente et al 2009</a>, <a class="bk_pop" href="#ccm.REF.campione.2013.2">Campione et al 2013</a>].</div></li></ul><p><b><i>CCM2</i>.</b> Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CCM2</i> have fewer brain lesions on GRE MRI, and the rate of lesion development is slower than in individuals with a heterozygous pathogenic variant in <i>KRIT1</i> [<a class="bk_pop" href="#ccm.REF.denier.2006.550">Denier et al 2006</a>].</p><p><b><i>PDCD10.</i></b> Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PDCD10</i> are most likely to present with hemorrhage and to have symptom onset before age 15 years [<a class="bk_pop" href="#ccm.REF.denier.2006.550">Denier et al 2006</a>, <a class="bk_pop" href="#ccm.REF.shenkar.2015.188">Shenkar et al 2015</a>].</p><ul><li class="half_rhythm"><div>Individuals with pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> generally have the most severe clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ccm.REF.riant.2013.165">Riant et al 2013</a>, <a class="bk_pop" href="#ccm.REF.shenkar.2015.188">Shenkar et al 2015</a>], including a higher risk of the following:</div><ul><li class="half_rhythm"><div>Lesion burden</div></li><li class="half_rhythm"><div>Skin lesions</div></li><li class="half_rhythm"><div>Scoliosis</div></li><li class="half_rhythm"><div>Brain tumors (meningioma, astrycytoma, acoustic neuroma)</div></li><li class="half_rhythm"><div>Cognitive disability unrelated to lesion burden or hemorrhage</div></li></ul></li></ul></div><div id="ccm.Penetrance"><h3>Penetrance</h3><p><b><i>KRIT1</i></b>. Among 64 families with 202 individuals who were <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>KRIT1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ccm.REF.denier.2004b.213">Denier et al 2004b</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">62% were symptomatic;</div></li><li class="half_rhythm"><div class="half_rhythm">58% of those who were at least age 50 years had symptoms related to CCM;</div></li><li class="half_rhythm"><div class="half_rhythm">45 of 53 symptom-free individuals had lesions on MRI (3 had indications of a type 4 lesion; see <a class="figpopup" href="/books/NBK1293/table/ccm.T.classification_of_ccm_by_mri_and_h/?report=objectonly" target="object" rid-figpopup="figccmTclassificationofccmbymriandh" rid-ob="figobccmTclassificationofccmbymriandh">Table 2</a>) and five had no clinical or MRI findings of CCM.</div><div class="half_rhythm">Note: SWI MRI, the most sensitive imaging technique for identifying CCMs, was not performed in this study.</div></li></ul><p><b><i>PDCD10</i>.</b> Penetrance may be decreased in families with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PDCD10</i> compared to families with a heterozygous pathogenic variant in <i>KRIT1</i> [<a class="bk_pop" href="#ccm.REF.denier.2006.550">Denier et al 2006</a>]. Penetrance may be specific to the pathogenic variant [<a class="bk_pop" href="#ccm.REF.gianfrancesco.2007.691">Gianfrancesco et al 2007</a>].</p></div><div id="ccm.Prevalence"><h3>Prevalence</h3><p>Based on autopsy studies, approximately 0.4%-0.5% of the general population have either <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CCM or FCCM [<a class="bk_pop" href="#ccm.REF.otten.1989.82">Otten et al 1989</a>, <a class="bk_pop" href="#ccm.REF.del_curling.1991.702">Del Curling et al 1991</a>, <a class="bk_pop" href="#ccm.REF.robinson.1991.709">Robinson et al 1991</a>]. The fairly common occurrence of asymptomatic vascular lesions in individuals with FCCM suggests that the population incidence of FCCM has been routinely underestimated [<a class="bk_pop" href="#ccm.REF.verlaan.2002a.853">Verlaan et al 2002a</a>, <a class="bk_pop" href="#ccm.REF.johnson.2004">Johnson et al 2004</a>].</p><p>There is a high incidence of FCCM in individuals of Mexican descent who have the pathogenic <a class="figpopup" href="/books/NBK1293/table/ccm.T.krit1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figccmTkrit1pathogenicvariantsdiscusse" rid-ob="figobccmTkrit1pathogenicvariantsdiscusse">p.Gln455Ter</a> variant in <i>KRIT1</i> &#x02013; a finding that could be attributable to inheritance from a common ancestor [<a class="bk_pop" href="#ccm.REF.johnson.1995.368">Johnson et al 1995</a>, <a class="bk_pop" href="#ccm.REF.gunel.1996.946">Gunel et al 1996</a>].</p></div></div><div id="ccm.Genetically_Related_Allelic_Disorder"><h2 id="_ccm_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i>.</p></div><div id="ccm.Differential_Diagnosis"><h2 id="_ccm_Differential_Diagnosis_">Differential Diagnosis</h2><p>CCMs represent 5%-15% of all cerebral vascular malformations [<a class="bk_pop" href="#ccm.REF.rigamonti.1988.343">Rigamonti et al 1988</a>]. Other vascular malformations occurring in the brain that should be distinguishable from CCM by neuroimaging and clinical manifestations:</p><ul><li class="half_rhythm"><div>Arteriovenous malformations</div></li><li class="half_rhythm"><div>Venous malformations</div></li><li class="half_rhythm"><div>Telangiectases</div></li><li class="half_rhythm"><div>Vascular tumors such as hemangioblastomas (including those seen in <a href="/books/n/gene/vhl/">Von Hippel-Lindau syndrome</a>)</div></li><li class="half_rhythm"><div>Vascular malformations associated with Sturge-Weber syndrome (OMIM <a href="http://omim.org/entry/185300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">185300</a>) [<a class="bk_pop" href="#ccm.REF.mohr.2005">Mohr &#x00026; Pile-Spellman 2005</a>]</div></li></ul><p>The finding of developmental venous anomalies (DVA) in association with CCM decreases the likelihood that an individual has FCCM [<a class="bk_pop" href="#ccm.REF.petersen.2010.377">Petersen et al 2010</a>].</p><p>The following acquired conditions may lead to brain imaging findings similar to those seen in individuals with CCM:</p><ul><li class="half_rhythm"><div>Hypertensive angiopathy</div></li><li class="half_rhythm"><div>Trauma</div></li><li class="half_rhythm"><div>Multiple hemorrhagic metastases</div></li><li class="half_rhythm"><div>Myloid angiopathy (with lacunar stroke)</div></li><li class="half_rhythm"><div>Pneumocephalus [<a class="bk_pop" href="#ccm.REF.palma.2009.e83">Palma et al 2009</a>]</div></li><li class="half_rhythm"><div>Cysticercosis</div></li></ul></div><div id="ccm.Management"><h2 id="_ccm_Management_">Management</h2><div id="ccm.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cerebral cavernous malformation (FCCM), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>MRI imaging of the brain and/or spinal cord if not already performed</div><ul><li class="half_rhythm"><div>Cerebral angiography may be considered to better define a complex lesion with arterial or venous components identified on brain MRI; however, caution should be used as cerebral angiography carries a small but appreciable risk of stroke.</div></li></ul></li><li class="half_rhythm"><div>In those with epilepsy:</div><ul><li class="half_rhythm"><div>Electoencephalogram (EEG) and/or video-EEG</div></li><li class="half_rhythm"><div>Wada testing (to determine which hemisphere is language dominant)</div></li><li class="half_rhythm"><div>Magnetoencephalography to confirm the localization of the epilepsy and to exclude other epileptogenic lesions</div></li></ul></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ccm.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Recurrent hemorrhage or mass effect.</b> Surgical removal of lesions associated with intractable seizures or focal deficits from recurrent hemorrhage or mass effect has traditionally been recommended [<a class="bk_pop" href="#ccm.REF.heros.2000">Heros &#x00026; Heros 2000</a>, <a class="bk_pop" href="#ccm.REF.selman.2000">Selman et al 2000</a>, <a class="bk_pop" href="#ccm.REF.folkersma.2001.67">Folkersma &#x00026; Mooij 2001</a>]; however, a recent large prospective study in Scotland reported that surgical excision increased the overall risk of short-term neurologic disability, symptomatic intracranial hemorrhage, and new focal neurosurgical deficits [<a class="bk_pop" href="#ccm.REF.moultrie.2014.582">Moultrie et al 2014</a>], calling this practice into question.</p><ul><li class="half_rhythm"><div>Neuropsychological testing may be considered prior to any neurosurgical procedure.</div></li><li class="half_rhythm"><div>Microsurgical techniques rely on intraoperative examination for precise localization.</div></li><li class="half_rhythm"><div>Even when a large number of lesions are present, a surgical approach may be justified.</div></li></ul><p><b>Gamma knife surgery or radiosurgery</b>, while effective, appears to increase the risk of recurrent hemorrhage and remains unproven [<a class="bk_pop" href="#ccm.REF.wang.2010.474">Wang et al 2010</a>, <a class="bk_pop" href="#ccm.REF.steiner.2010.16">Steiner et al 2010</a>]. Very large single lesions can be difficult to ablate, especially in the brain stem. In these instances, radiosurgery may be an option [<a class="bk_pop" href="#ccm.REF.monaco.2010.e11">Monaco et al 2010</a>].</p><ul><li class="half_rhythm"><div>In a group of individuals with symptomatic cavernous malformations studied in Japan, radiosurgery using varying doses of radiation for deep lesions was compared with conservative (nonsurgical) management. Doses less than 15 Gray (Gy) were associated with the lowest level of complications. Complications were also lower when the lesions were of smaller size, with overall hemorrhage rates reduced initially but reverting to a rate similar to that of the natural history after the first two years post-radiosurgery [<a class="bk_pop" href="#ccm.REF.kida.2015.s249">Kida et al 2015</a>].</div></li><li class="half_rhythm"><div>A study that carefully reviewed post-radiosurgery changes in individuals with CCM or AVM found that more than 30% developed radiation necrosis [<a class="bk_pop" href="#ccm.REF.blamek.2010.187">Blamek et al 2010</a>].</div></li></ul><p><b>Seizures.</b> Standard treatment for focal seizures using antiepileptic medication with early evaluation for surgical resection is appropriate (see <a href="#ccm.Treatment_of_Manifestations">Recurrent hemorrhage or mass effect</a>).</p><p><b>Headaches.</b> Standard treatment and management of headaches is indicated unless the headache is severe, prolonged, or progressive, or associated with new or worsening neurologic deficits. In this circumstance, urgent brain imaging could lead to surgical management.</p><p><b>Neurologic deficits.</b> Rehabilitation is indicated for those with temporary or permanent neurologic deficits.</p></div><div id="ccm.Surveillance"><h3>Surveillance</h3><p>Brain MRI imaging with GRE or SWI is indicated in individuals experiencing new neurologic symptoms. Interpretation can be difficult because new hemorrhages may be asymptomatic.</p></div><div id="ccm.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Limited evidence suggests an increased risk of hemorrhage with certain analgesic medications such as nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) and aspirin. Individuals with headaches and other pain should avoid these medications if suitable substitutes are available.</p><p>Other medications that increase risk of hemorrhage (e.g., heparin, sodium warfarin [Coumadin<sup>&#x000ae;</sup>]) should be avoided or, when such medications are necessary for treatment of life-threatening thrombosis, should be closely monitored by the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's medical team [<a class="bk_pop" href="#ccm.REF.schneble.2012.3196">Schneble et al 2012</a>, <a class="bk_pop" href="#ccm.REF.flemming.2013.43">Flemming et al 2013</a>, <a class="bk_pop" href="#ccm.REF.erdur.2014.1846">Erdur et al 2014</a>].</p><p>The use of narcotic pain medications is also discouraged in chronic pain conditions because of the potential for addiction and because of their association with rebound headaches.</p><p>Radiation to the central nervous system is associated with <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> lesion formation in FCCM [<a class="bk_pop" href="#ccm.REF.larson.1998.51">Larson et al 1998</a>, <a class="bk_pop" href="#ccm.REF.nimjee.2006.e4">Nimjee et al 2006</a>, <a class="bk_pop" href="#ccm.REF.golden.2015.134">Golden et al 2015</a>]. The pathology of these lesions appears to be histologically different from the cavernomas found prior to radiation [<a class="bk_pop" href="#ccm.REF.cha.2015.1714">Cha et al 2015</a>].</p></div><div id="ccm.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate both symptomatic and apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from initiation of screening and preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known.</div></li><li class="half_rhythm"><div>Brain and/or spinal cord MRI imaging including GRE or SWI if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known</div></li></ul><p>See <a href="#ccm.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ccm.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnant women with FCCM who have had recent brain or spinal cord hemorrhage, epilepsy, or migraine will require closer observation during pregnancy. Baseline MRI one year prior to delivery is recommended to determine lesion locations [<a class="bk_pop" href="#ccm.REF.de_jong.2012.635">De Jong et al 2012</a>, <a class="bk_pop" href="#ccm.REF.witiw.2012.626">Witiw et al 2012</a>, <a class="bk_pop" href="#ccm.REF.yamada.2013.555">Yamada et al 2013</a>].</p><p><a class="bk_pop" href="#ccm.REF.simonazzi.2014.261">Simonazzi et al [2014]</a> reported six women with CCM who had symptoms such as seizure or focal neurologic deficit during pregnancy or within six weeks post-delivery. Reviewing the literature they found ten further cases in which pregnancy outcome was published. Of the 16 women, hemorrhage occured in ten. Preterm delivery occurred in four of six cases, one because of neurologic symptoms at 30 weeks. C&#x000e6;sarean (C-)section was performed in nine cases, eight of which were for concern over CCM.</p><p>Affected women and obstetricians are frequently concerned that the risk of increased blood pressure and intrathoracic pressure during stage 3 labor (pushing phase) could lead to CCM hemorrhage. However, in a study of 168 pregnancies (64 women), 28 with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> CCM and 36 with FCCM, only five symptomatic cerebral hemorrhages were reported, most commonly manifesting as seizures. Nineteen deliveries in this study were by C-section, mostly due to fear of possible intracranial hemorrhage. The risk of CCM hemorrhage was higher in the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases (3.6% compared with 1.8% in sporadic cases) [<a class="bk_pop" href="#ccm.REF.kalani.2013.50">Kalani &#x00026; Zabramski 2013</a>].</p><p>In general, women with epilepsy or a seizure disorder from any cause are at greater risk for mortality during pregnancy than pregnant women without a seizure disorder; use of antiepileptic medication during pregnancy reduces this risk. However, exposure to antiepileptic medication may increase the risk for adverse fetal outcome (depending on the drug used, the dose, and the stage of pregnancy at which medication is taken). Nevertheless, the risk of an adverse outcome to the fetus from medication exposure is often less than that associated with exposure to an untreated maternal seizure disorder. Therefore, use of antiepileptic medication during pregnancy is typically recommended. Discussion of the risks and benefits of using a given antiepileptic drug during pregnancy should ideally take place prior to conception. Transitioning to a lower-risk medication prior to pregnancy may be possible [<a class="bk_pop" href="#ccm.REF.sarma.2016.467">Sarma et al 2016</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="ccm.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Recent advances in the understanding of the pathobiology and molecular signaling of the CCM proteins (see <a href="#ccm.Molecular_Genetics">Molecular Genetics</a>) has identified several pathways which may be amenable to drug targeting. These are being investigation in in vitro assays and in live animal models.</p><p>Fasudil, a specific Rho kinase inhibitor, has been demonstrated in <i>Krit1</i>(+/-) and <i>Ccm2</i> (+/-) mouse models of FCCM to reduce both lesion size and number, as well as to lesson hemorrhage, proliferation, and inflammation [<a class="bk_pop" href="#ccm.REF.stockton.2010.881">Stockton et al 2010</a>, <a class="bk_pop" href="#ccm.REF.mcdonald.2012.571">McDonald et al 2012</a>]. Fasudil is approved in Japan for treatment of vasodilation; it is not currently available with FDA approval in the United States.</p><p>Statin medications are nonspecific Rho kinase inhibitors and may be suitable for repurposing to treat CCM lesions. Strong in vitro data [<a class="bk_pop" href="#ccm.REF.whitehead.2009.177">Whitehead et al 2009</a>] led to simvastatin being studied in people with CCM who are eligible to take this medication for other indications such as hyperlipidemia. This trial is in the final data collection and analysis phase (ClinicalTrials.gov identifier: NCT01764451). However, a <i>Ccm2</i> knockout mouse model treated with simvastatin did not show a significant decrease in lesion burden, raising questions about dosing and efficacy of statin drug therapy [<a class="bk_pop" href="#ccm.REF.gibson.2015.289">Gibson et al 2015</a>]. A further proof-of-concept human trial is planned for atorvastatin therapy (ClinicalTrials.gov identifier: NCT02603328).</p><p>The chemotherapeutic drug sorafenib [<a class="bk_pop" href="#ccm.REF.w_stehube.2010.12640">W&#x000fc;stehube et al 2010</a>] has been investigated in murine models of FCCM caused by mutation of <i>KRIT1</i> with the finding of reduced capillary sprouting.</p><p>Loss of function of KRIT1 leads to an increase in signaling of the TGF&#x003b2; pathway leading to an inappropriate endothelial-to-mesenchymal cellular transition (EndMT): endothelial cells change to become more proliferative, with increased invasiveness and sprouting. Chemical inhibition of TGF&#x003b2; decreases both the size and number of CCM lesions in mouse models [<a class="bk_pop" href="#ccm.REF.maddaluno.2013.492">Maddaluno et al 2013</a>]. Furthermore, inhibition of upstream Wnt/B-Catenin signaling related to EndMT with the drug sulindac restores junctional integrity between endothelia, and also reduces number and size of CCM lesions in a <i>Pdcd10</i> knockout mouse model [<a class="bk_pop" href="#ccm.REF.bravi.2015.8421">Bravi et al 2015</a>]. Sulindac is used clinically in humans for other indications, including for the treatment of colon cancer.</p><p>A repurposing drug screen identified vitamin D<sub>3</sub> (cholecalciferol) and tempol (a superoxide scavenger) as potential therapeutic drugs for CCM. Both of these molecules reduced lesion number in mouse models of CCM [<a class="bk_pop" href="#ccm.REF.gibson.2015.289">Gibson et al 2015</a>]. Vitamin D<sub>3</sub> inhibits the signaling activation of RHOA, while tempol targets superoxide, suggesting a role for oxidative stress in CCM disease pathogenesis.</p><p>Search <a href="http://www.ClinicalTrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ccm.Genetic_Counseling"><h2 id="_ccm_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ccm.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Familial cerebral cavernous malformation (FCCM) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="ccm.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Many individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> CCM have a symptomatic parent. However, the fairly common occurrence of asymptomatic vascular lesions may prevent recognition of an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pattern of inheritance in a family [<a class="bk_pop" href="#ccm.REF.denier.2004b.213">Denier et al 2004b</a>].</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with FCCM may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown, as the frequency of subtle signs of the disorder in parents has not been thoroughly evaluated and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> data are insufficient. Individuals with a <i>de novo</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant &#x02013; most commmonly in <i>PDCD10</i> &#x02013; have been reported [<a class="bk_pop" href="#ccm.REF.lucas.2001.529">Lucas et al 2001</a>, <a class="bk_pop" href="#ccm.REF.denier.2004b.213">Denier et al 2004b</a>, <a class="bk_pop" href="#ccm.REF.liquori.2008.25">Liquori et al 2008</a>, <a class="bk_pop" href="#ccm.REF.stahl.2008.709">Stahl et al 2008</a>, <a class="bk_pop" href="#ccm.REF.shenkar.2015.188">Shenkar et al 2015</a>].</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and/or brain MRI including GRE or SWI. Family history may help to determine which parent is most likely to require laboratory/diagnostic examination.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with FCCM may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in the parent with the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations (i.e., <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the pathogenic variant has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and/or brain MRI including GRE or SWI) has been performed on the parents of the proband.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents:</div><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with no clinical symptoms, the risk to each sib of inheriting the pathogenic variant is 50%.</div></li><li class="half_rhythm"><div>If the <i>KRIT1, CCM2</i>, or <i>PDCD10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li></ul></li><li class="half_rhythm"><div>Since more than 5% of individuals with multiple lesions and/or a family history of CCMs do not have an identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in any of the three genes known to be associated with FCCM, the assumption of a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> form must be made and sibs and parents offered brain MRI with GRE and/or SWI.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with FCCM has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="ccm.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ccm.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with FCCM has the pathogenic variant or clinical evidence of the disorder, the <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> pathogenic variant is likely <i>de novo</i>. However, other possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (see <a href="http://angiomaalliance.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">angiomaalliance.org</a>).</p></div><div id="ccm.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ccm.Resources"><h2 id="_ccm_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Angioma Alliance</b></div><div>520 West 21st Street</div><div>Suite G2-411</div><div>Norfolk VA 23517-1950</div><div><b>Fax:</b> 757-623-0616</div><div><b>Email:</b> info@angioma.org</div><div><a href="http://angiomaalliance.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">angiomaalliance.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=cerebralcavernousmalformation" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cerebral cavernous malformation</a></div></li><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>Angioma Alliance DNA/Tissue Bank</b></div><div><i>The DNA/Tissue Bank provides researchers with biological samples and medical history for research projects.</i></div><div><a href="http://www.angioma.org/registry.aspx?content=99" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.angioma.org/DNA</a></div></li><li class="half_rhythm"><div><b>International Cavernous Angioma Patient Registry</b></div><div><i>This registry is developed and supported by Angioma Alliance.</i></div><div><a href="https://angioma.patientcrossroads.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Cavernous Angioma Patient Registry</a></div></li></ul></div><div id="ccm.Molecular_Genetics"><h2 id="_ccm_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ccm.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Familial Cerebral Cavernous Malformation: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ccm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_ccm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ccm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ccm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ccm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ccm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ccm.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ccm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">CCM1</td><td headers="hd_b_ccm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/889" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KRIT1</i></a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q21<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O00522" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Krev interaction trapped protein 1</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KRIT1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRIT1 database</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRIT1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRIT1</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRIT1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRIT1</a></td></tr><tr><td headers="hd_b_ccm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">CCM2</td><td headers="hd_b_ccm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/83605" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CCM2</i></a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=83605" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7p13</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BSQ5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cerebral cavernous malformations 2 protein</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CCM2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCM2 database</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CCM2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCM2</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CCM2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCM2</a></td></tr><tr><td headers="hd_b_ccm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">CCM3</td><td headers="hd_b_ccm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/11235" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PDCD10</i></a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=11235" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q26<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9BUL8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Programmed cell death protein 10</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/PDCD10" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PDCD10 database</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PDCD10" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PDCD10</a></td><td headers="hd_b_ccm.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PDCD10[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PDCD10</a></td></tr><tr><td headers="hd_b_ccm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">CCM4</td><td headers="hd_b_ccm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Unknown</td><td headers="hd_b_ccm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">3q26.3-27.2</td><td headers="hd_b_ccm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Unknown</td><td headers="hd_b_ccm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_ccm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_ccm.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ccm.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ccm.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Familial Cerebral Cavernous Malformation (<a href="/omim/116860,603284,603285,604214,607929,609118" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/116860" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">116860</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CAVERNOUS MALFORMATIONS; CCM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603284" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603284</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CAVERNOUS MALFORMATIONS 2; CCM2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603285" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603285</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604214" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604214</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KREV INTERACTION TRAPPED 1; KRIT1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607929" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607929</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CCM2 GENE; CCM2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609118" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609118</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROGRAMMED CELL DEATH 10; PDCD10</td></tr></tbody></table></div></div><div id="ccm.Overview"><h3>Overview</h3><p>A single inherited <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of three genes &#x02013; <i>KRIT1</i> (<i>CCM1</i>), <i>CCM2</i>, or <i>PDCD10</i> (<i>CCM3</i>) &#x02013; is sufficient to cause <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cerebral cavernous malformation (FCCM); however, the precise molecular mechanisms that leads to the formation of CCM lesions remains unclear. It is known that the proteins encoded by these genes are essential for blood vessel growth and development. Additionally, these molecules serve a variety of roles within cells related to maintaining proper cellular shape, integrity, and behavior. A better understanding of the function of these genes has identified and will continue to identify druggable pathways that can be targeted for clinical research. Several promising drug candidates are currently under investigation in mice.</p><div id="ccm.KRIT1"><h4><i>KRIT1</i></h4><p><b>Gene structure.</b>
<i>KRIT1</i>, previously known as <i>CCM1,</i> comprises 16 coding exons. See <a href="/books/NBK1293/#ccm.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> More than 100 pathogenic variants that predict loss of function have been published to date [<a class="bk_pop" href="#ccm.REF.cav_riant.2002.733">Cav&#x000e9;-Riant et al 2002</a>, <a class="bk_pop" href="#ccm.REF.verlaan.2002a.853">Verlaan et al 2002a</a>, <a class="bk_pop" href="#ccm.REF.denier.2004a.326">Denier et al 2004a</a>, <a class="bk_pop" href="#ccm.REF.revencu.2006.716">Revencu &#x00026; Vikkula 2006</a>, <a class="bk_pop" href="#ccm.REF.guarnieri.2007.29">Guarnieri et al 2007</a>, <a class="bk_pop" href="#ccm.REF.kuhn.2009.154">Kuhn et al 2009</a>, <a class="bk_pop" href="#ccm.REF.riant.2013.165">Riant et al 2013</a>]; 50% are frameshifts, 24% are <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and 24% are changes in the invariant splice junctions. The pathogenic variants are evenly distributed across the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, with no evidence of hot spots.</p><p>CCM cohorts who had no detectable <i>KRIT1</i>, <i>CCM2</i>, or <i>PDCD10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> had (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions of <i>KRIT1</i> at a frequency of 5% in the US, 4% in France, and 50% in Italy [<a class="bk_pop" href="#ccm.REF.liquori.2008.25">Liquori et al 2008</a>, <a class="bk_pop" href="#ccm.REF.riant.2013.165">Riant et al 2013</a>].</p><p>Two founder pathogenic variants have been identified:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1293/table/ccm.T.krit1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figccmTkrit1pathogenicvariantsdiscusse" rid-ob="figobccmTkrit1pathogenicvariantsdiscusse">p.Gln455Ter</a>, referred to as the "common Hispanic variant," was identified in about 70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families of Hispanic heritage descending from the original settlers of the American southwest (16/21 individuals) [<a class="bk_pop" href="#ccm.REF.sahoo.1999.2325">Sahoo et al 1999</a>].</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1293/table/ccm.T.krit1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figccmTkrit1pathogenicvariantsdiscusse" rid-ob="figobccmTkrit1pathogenicvariantsdiscusse">p.Cys329Ter</a> was identified in four families in Sardinia [<a class="bk_pop" href="#ccm.REF.cau.2009.344">Cau et al 2009</a>].</div></li></ul><p>Consistent with <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants, four pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants activate cryptic splice sites with aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <i>KRIT1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and frameshift with a premature stop codon [<a class="bk_pop" href="#ccm.REF.sahoo.1999.2325">Sahoo et al 1999</a>, <a class="bk_pop" href="#ccm.REF.verlaan.2002b.1564">Verlaan et al 2002b</a>, <a class="bk_pop" href="#ccm.REF.riant.2010.1070">Riant et al 2010</a>].</p><div id="ccm.T.krit1_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>KRIT1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.T.krit1_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.T.krit1_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.987C&#x0003e;A</td><td headers="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys329Ter</td><td headers="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_194456.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_194456<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/protein/NP_919438.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_919438<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1363C&#x0003e;T</td><td headers="hd_h_ccm.T.krit1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln455Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The KRIT1 protein is 736 amino acids in length. KRIT1 has a variety of functions within the vascular system and throughout the body. This anchor protein has been demonstrated to have a role in regulating cell structure and responding to shear stress through the integrin signaling pathway [<a class="bk_pop" href="#ccm.REF.zawistowski.2002.389">Zawistowski et al 2002</a>, <a class="bk_pop" href="#ccm.REF.macek_jilkova.2014.1228">Macek Jilkova et al 2014</a>], maintaining homeostasis of intracellular reactive oxygen species [<a class="bk_pop" href="#ccm.REF.goitre.2010.e11786">Goitre et al 2010</a>, <a class="bk_pop" href="#ccm.REF.goitre.2014.134">Goitre et al 2014</a>], and regulating autophagy by activating the mTOR pathway [<a class="bk_pop" href="#ccm.REF.marchi.2015.1403">Marchi et al 2015</a>].</p><p>Within human endothelium, KRIT1 regulates endothelial cell-cell junctions to maintain junctional stability and control of vascular permeability in response to inflammation [<a class="bk_pop" href="#ccm.REF.glading.2007.247">Glading et al 2007</a>, <a class="bk_pop" href="#ccm.REF.borikova.2010.11760">Borikova et al 2010</a>, <a class="bk_pop" href="#ccm.REF.corr.2012.2702">Corr et al 2012</a>]. KRIT1 can activate angiogenesis through Delta-Notch signaling [<a class="bk_pop" href="#ccm.REF.w_stehube.2010.12640">W&#x000fc;stehube et al 2010</a>, <a class="bk_pop" href="#ccm.REF.distefano.2014.33054">DiStefano et al 2014</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in this gene predict a premature termination of translation, which supports a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism [<a class="bk_pop" href="#ccm.REF.verlaan.2002a.853">Verlaan et al 2002a</a>].</p><p>Loss of KRIT1 function leads to CCM lesion genesis. Loss of KRIT1 alters cellular signaling and changes cellular behavior. In the absence of KRIT1, endothelial cells become more stem cell-like, proliferative, and invasive [<a class="bk_pop" href="#ccm.REF.maddaluno.2013.492">Maddaluno et al 2013</a>].</p><p>Understanding pathways involved in KRIT1 signaling may lead to potentially druggable targets to develop therapeutics to prevent bleeding from and genesis of CCM lesions.</p></div><div id="ccm.CCM2"><h4><i>CCM2</i></h4><p><b>Gene structure.</b>
<i>CCM2</i> has ten coding exons, with an alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1B. See <a href="/books/NBK1293/#ccm.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> The majority of <i>CCM2</i> pathogenic variants predict inactivation of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or the protein product. Most pathogenic variants are single-base changes or small indels that are readily identifiable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. However, a 77.6-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that includes exons 2-10 is a common founder deletion in the US population (see <a class="figpopup" href="/books/NBK1293/table/ccm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figccmTmoleculargenetictestingusedin" rid-ob="figobccmTmoleculargenetictestingusedin">Table 1</a>, footnote 7) is not identifiable by sequence analysis.</p><p>Among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>KRIT1</i>, <i>CCM2</i>, and <i>PDCD10</i>, a <i>CCM2</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or multiexon <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was detected in 95% of those in the US and in 40% of Italians [<a class="bk_pop" href="#ccm.REF.liquori.2008.25">Liquori et al 2008</a>].</p><div id="ccm.T.ccm2_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>CCM2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1293/table/ccm.T.ccm2_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ccm.T.ccm2_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.30+5_30+6delGCinsTT</td><td headers="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_031443.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_031443<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_113631.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_113631<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77.6-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a></td><td headers="hd_h_ccm.T.ccm2_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Cerebral cavernous malformations 2 protein, a protein with a PTB (phospho-tyrosine binding) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> encoded by <i>CCM2,</i> binds to and regulates the localization of KRIT1. Cerebral cavernous malformations 2 protein is a scaffold protein for multiple signaling cascades including the p38 mitogen-activated protein kinase (MAPK) signaling [<a class="bk_pop" href="#ccm.REF.uhlik.2003.1104">Uhlik et al 2003</a>, <a class="bk_pop" href="#ccm.REF.fisher.2015.7937">Fisher et al 2015</a>] and Rho kinase signaling for maintenance of proper vascular integrity [<a class="bk_pop" href="#ccm.REF.whitehead.2009.177">Whitehead et al 2009</a>, <a class="bk_pop" href="#ccm.REF.borikova.2010.11760">Borikova et al 2010</a>, <a class="bk_pop" href="#ccm.REF.stockton.2010.881">Stockton et al 2010</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>CCM2</i> result in or predict loss of function. Animal models and molecular studies support the mode of action for <i>CCM2</i> pathogenic variants to follow a two-hit genetic mechanism [<a class="bk_pop" href="#ccm.REF.akers.2009.919">Akers et al 2009</a>, <a class="bk_pop" href="#ccm.REF.pagenstecher.2009.911">Pagenstecher et al 2009</a>, <a class="bk_pop" href="#ccm.REF.whitehead.2009.177">Whitehead et al 2009</a>].</p></div><div id="ccm.PDCD10"><h4><i>PDCD10</i></h4><p><b>Gene structure.</b>
<i>PDCD10,</i> formerly known as <i>CCM3,</i> has ten exons; the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> starts with <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4. See <a href="/books/NBK1293/#ccm.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b>
<a class="bk_pop" href="#ccm.REF.bergametti.2005.42">Bergametti et al [2005]</a> originally described seven distinct pathogenic variants in eight families: one <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, one abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5, three pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, and two pathogenic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. Consistent with this allelic series, all other identified <i>PDCD10</i> pathogenic variants result in or predict <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> alleles. CCM cohorts that had no detectable <i>KRTI1</i>, <i>CCM2</i>, or <i>PDCD10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> had exon or multiexon deletions at a frequency of 0% in the US vs 10% in Italy [<a class="bk_pop" href="#ccm.REF.liquori.2008.25">Liquori et al 2008</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PDCD10</i> encodes a 212-amino acid adaptor protein, programmed cell death 10 (PDCD10), with no known functional domains. PDCD10 plays a role in apoptosis; PDCD10 overexpression leads to activation of caspase 3 and increased cell death [<a class="bk_pop" href="#ccm.REF.wang.1999.323">Wang et al 1999</a>, <a class="bk_pop" href="#ccm.REF.guclu.2005.1008">Guclu et al 2005</a>].</p><p>PDCD10 is involved in a wide variety of cellular signaling processes and has been shown to be part of the macromolecular complex including KRIT1 and cerebral cavernous malformations 2 protein [<a class="bk_pop" href="#ccm.REF.hilder.2007.4343">Hilder et al 2007</a>, <a class="bk_pop" href="#ccm.REF.voss.2007.249">Voss et al 2007</a>]. Within the vasculature, PDCD10 plays a critical role in vascular development (through VEGF signaling) and regulation of angiogenesis (through DLL4-Notch signaling) [<a class="bk_pop" href="#ccm.REF.he.2010.ra26">He et al 2010</a>, <a class="bk_pop" href="#ccm.REF.you.2013.407">You et al 2013</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The nature of the pathogenic variants detected to date (<a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> alleles) suggests a role for <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> or somatic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> [<a class="bk_pop" href="#ccm.REF.akers.2009.919">Akers et al 2009</a>, <a class="bk_pop" href="#ccm.REF.pagenstecher.2009.911">Pagenstecher et al 2009</a>].</p></div></div></div><div id="ccm.References"><h2 id="_ccm_References_">References</h2><div id="ccm.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.abla.2010.1589">Abla AA, Lekovic GP, Garrett M, Wilson DA, Nakaji P, Bristol R, Spetzler RF. Cavernous malformations of the brainstem presenting in childhood: surgical experience in 40 patients. <span><span class="ref-journal">Neurosurgery. </span>2010;<span class="ref-vol">67</span>:1589–98.</span> [<a href="/pubmed/21107189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21107189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.acciarri.2009.81">Acciarri N, Galassi E, Giulioni M, Pozzati E, Grasso V, Palandri G, Badaloni F, Zucchelli M, Calbucci F. Cavernous malformations of the central nervous system in the pediatric age group. <span><span class="ref-journal">Pediatr Neurosurg. </span>2009;<span class="ref-vol">45</span>:81–104.</span> [<a href="/pubmed/19307743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19307743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.akers.2009.919">Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:919–30.</span> [<a href="/pmc/articles/PMC2640209/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640209</span></a>] [<a href="/pubmed/19088123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19088123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.alholou.2012.198">Al-Holou WN, O'Lynnger TM, Pandey AS, Gemmete JJ, Thompson BG, Muraszko KM, Garton HJ, Maher CO. Natural history and imaging prevalence of cavernous malformations in children and young adults. <span><span class="ref-journal">J Neurosurg Pediatr. </span>2012;<span class="ref-vol">9</span>:198–205.</span> [<a href="/pubmed/22295927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22295927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.alshahi_salman.2008.3222">Al-Shahi Salman R, Berg MJ, Morrison L, Awad IA., Angioma Alliance Scientific Advisory Board.  Hemorrhage from cavernous malformations of the brain: definition and reporting standards - Angioma Alliance Scientific Advisory Board. <span><span class="ref-journal">Stroke. </span>2008;<span class="ref-vol">39</span>:3222–30.</span> [<a href="/pubmed/18974380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18974380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.ardeshiri.2008.11">Ardeshiri A, Ardeshiri A, Beiras-Fernandez A, Steinlein OK, Winkler PA. Multiple cerebral cavernous malformations associated with extracranial mesenchymal anomalies. <span><span class="ref-journal">Neurosurg Rev. </span>2008;<span class="ref-vol">31</span>:11–7.</span> [<a href="/pubmed/17957396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17957396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.badhiwala.2014.662">Badhiwala JH, Farrokhyar F, Alhazzani W, Yarascavitch B, Aref M, Algird A, Murty N, Kachur E, Cenic A, Reddy K, Almenawer SA. Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data: Clinic article. <span><span class="ref-journal">J Neurosurg Spine. </span>2014;<span class="ref-vol">21</span>:662–76.</span> [<a href="/pubmed/25062285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25062285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.battistini.2007.843">Battistini S, Rocchi R, Cerase A, Citterio A, Tassi L, Lando G, Patrosso MC, Galli R, Brunori P, Sgr&#x000f2; DL, Pitillo G, Lo Russo G, Marocchi A, Penco S. Clinical, magnetic resonance imaging, and genetic study of 5 Italian families with cerebral cavernous malformation. <span><span class="ref-journal">Arch Neurol. </span>2007;<span class="ref-vol">64</span>:843–8.</span> [<a href="/pubmed/17562932" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17562932</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.bergametti.2005.42">Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, Jacquet G, Lonjon M, Moreau JJ, Neau JP, Parker F, Tremoulet M, Tournier-Lasserve E. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">76</span>:42–51.</span> [<a href="/pmc/articles/PMC1196432/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1196432</span></a>] [<a href="/pubmed/15543491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15543491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.bhardwaj.2009.458">Bhardwaj RD, Auguste KI, Kulkarni AV, Dirks PB, Drake JM, Rutka JT. Management of pediatric brainstem cavernous malformations: experience over 20 years at the hospital for sick children. <span><span class="ref-journal">J Neurosurg Pediatr. </span>2009;<span class="ref-vol">4</span>:458–64.</span> [<a href="/pubmed/19877780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19877780</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.bilo.2016.962">Bilo L, Antenora A, Peluso S, Procaccini EM, Quarantelli M, Mansueto G, Cigoli MS, Penco S, De Michele G. CCM3/PDCD10 gene mutation in cerebral cavernous malformations associated with hyperkeratotic cutaneous capillary venous malformations. <span><span class="ref-journal">J Dermatol. </span>2016;<span class="ref-vol">43</span>:962–3.</span> [<a href="/pubmed/26896283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26896283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.blamek.2010.187">Blamek S, Boba M, Larysz D, Rudnik A, Ficek K, Eksner B, Miszczyk L, Tarnawski R. The incidence of imaging abnormalities after stereotactic radiosurgery for cerebral arteriovenous and cavernous malformations. <span><span class="ref-journal">Acta Neurochir Suppl. </span>2010;<span class="ref-vol">106</span>:187–90.</span> [<a href="/pubmed/19812946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19812946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.borikova.2010.11760">Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:11760–4.</span> [<a href="/pmc/articles/PMC2852911/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2852911</span></a>] [<a href="/pubmed/20181950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20181950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.bravi.2015.8421">Bravi L, Rudini N, Cuttano R, Giampietro C, Maddaluno L, Ferrarini L, Adams RH, Corada M, Boulday G, Tournier-Lasserve E, Dejana E, Lampugnani MG. Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2015;<span class="ref-vol">112</span>:8421–6.</span> [<a href="/pmc/articles/PMC4500248/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4500248</span></a>] [<a href="/pubmed/26109568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26109568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.brownlee.2014.e133">Brownlee WJ, Roxburgh R. Mystery Case: Cutaneous lesions in KRIT1-associated cerebral cavernous malformations. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:e133–4.</span> [<a href="/pubmed/25267988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25267988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.brunereau.2000.475">Brunereau L, Levy C, Laberge S, Houtteville J, Labauge P. De novo lesions in familial form of cerebral cavernous malformations: clinical and MR features in 29 non-Hispanic families. <span><span class="ref-journal">Surg Neurol. </span>2000;<span class="ref-vol">53</span>:475–82.</span> [<a href="/pubmed/10874147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10874147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.bulut.2014.5296">Bulut HT, Sarica MA, Baykan AH. The value of susceptibility weighted Magnetic resonance imagin in evaluation of patients with familial cerebral cavernous angioma. <span><span class="ref-journal">Int J Clin Exp Med. </span>2014;<span class="ref-vol">7</span>:5296–302.</span> [<a href="/pmc/articles/PMC4307481/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4307481</span></a>] [<a href="/pubmed/25664034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25664034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.campione.2013.2">Campione E, Diluvio L, Terrinoni A, Di Stefani A, Orlandi A, Chimenti S, Bianchi L. Progressive late-onset of cutaneous angiomatosis as possible sign of cerebral cavernous malformations. <span><span class="ref-journal">Dermatol Online J. </span>2013;<span class="ref-vol">19</span>:2.</span> [<a href="/pubmed/23473272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23473272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cau.2009.344">Cau M, Loi M, Melis M, Congiu R, Loi A, Meloni C, Serrenti M, Addis M, Melis MA. C329X in KRIT1 is a founder mutation among CCM patients in Sardinia. <span><span class="ref-journal">Eur J Med Genet. </span>2009;<span class="ref-vol">52</span>:344–8.</span> [<a href="/pubmed/19454328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19454328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cav_riant.2002.733">Cav&#x000e9;-Riant F, Denier C, Labauge P, C&#x000e9;cillon M, Maciazek J, Joutel A, Laberge-Le Couteulx S, Tournier-Lasserve E. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with Cerebral Cavernous Malformations. <span><span class="ref-journal">Eur J Hum Genet. </span>2002;<span class="ref-vol">10</span>:733–40.</span> [<a href="/pubmed/12404106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12404106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cha.2015.1714">Cha YJ, Nahm JH, Ko JE, Shin HJ, Chang JH, Cho NH, Kim SH. Pathological Evaluation of Radiation-Induced Vascular Lesions of the Brain: Distinct from De Novo Cavernous Hemangioma. <span><span class="ref-journal">Yonsei Med J. </span>2015;<span class="ref-vol">56</span>:1714–20.</span> [<a href="/pmc/articles/PMC4630064/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4630064</span></a>] [<a href="/pubmed/26446658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26446658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.chen.2002.91">Chen DH, Lipe HP, Qin Z, Bird TD. Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity. <span><span class="ref-journal">J Neurol Sci. </span>2002;<span class="ref-vol">196</span>:91–6.</span> [<a href="/pubmed/11959162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11959162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cigoli.2014.e110438">Cigoli MS, Avemaria F, De Benedetti S, Gesu GP, Accorsi LG, Parmigiani S, Corona MF, Capra V, Mosca A, Giovannini S, Notturno F, Ciccocioppo F, Volpi L, Estienne M, De Michele G, Antenora A, Bilo L, Tavoni A, Zamponi N, Alfei E, Baranello G, Riva D, Penco S. PDCD10 gene mutations in multiple cerebral cavernous malformations. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e110438.</span> [<a href="/pmc/articles/PMC4212902/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4212902</span></a>] [<a href="/pubmed/25354366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25354366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cohengadol.2006.376">Cohen-Gadol AA, Jacob JT, Edwards DA, Krauss WE. Coexistence of intracranial and spinal cavernous malformations: a study of prevalence and natural history. <span><span class="ref-journal">J Neurosurg. </span>2006;<span class="ref-vol">104</span>:376–81.</span> [<a href="/pubmed/16572649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16572649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.cooper.2008.382">Cooper AD, Campeau NG, Meissner I. Susceptibility-weighted imaging in familial cerebral cavernous malformations. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">71</span>:382.</span> [<a href="/pubmed/18663188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18663188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.corr.2012.2702">Corr M, Lerman I, Keubel JM, Ronacher L, Misra R, Lund F, Sarelius IH, Glading AJ. Decreased Krev interaction-trapped 1 expression leads to increased vascular permeability and modifies inflammatory responses in vivo. <span><span class="ref-journal">Arterioscler Thromb Vasc Biol. </span>2012;<span class="ref-vol">32</span>:2702–10.</span> [<a href="/pmc/articles/PMC3475761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3475761</span></a>] [<a href="/pubmed/22922958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22922958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.dangelo.2011.215">D'Angelo R, Marini V, Rinaldi C, Origone P, Dorcaratto A, Avolio M, Goitre L, Forni M, Capra V, Alafaci C, Mareni C, Garr&#x000e8; C, Bramanti P, Sidoti A, Retta SF, Amato A. Mutation analysis of CCM1, CCM2 and CCM3 genes in a cohort of Italian patients with cerebral cavernous malformation. <span><span class="ref-journal">Brain Pathol. </span>2011;<span class="ref-vol">21</span>:215–24.</span> [<a href="/pubmed/21029238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21029238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.de_jong.2012.635">De Jong A, Benayoun L, Bekrar Y, Forget S, Wernet A. Obstetric anaesthesia in two patients with cerebral cavernomas: about two cases. <span><span class="ref-journal">Ann Fr Anesth Reanim. </span>2012;<span class="ref-vol">31</span>:635–7.</span> [<a href="/pubmed/22749550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22749550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.de_souza.2008.154">de Souza JM, Domingues RC, Cruz LC Jr, Domingues FS, Iasbeck T, Gasparetto EL. Susceptibility-weighted imaging for the evaluation of patients with familial cerebral cavernous malformations: a comparison with T2-weighted fast spin-echo and gradient-echo sequences. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2008;<span class="ref-vol">29</span>:154–8.</span> [<a href="/pubmed/17947370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17947370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.del_curling.1991.702">Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. <span><span class="ref-journal">J Neurosurg. </span>1991;<span class="ref-vol">75</span>:702–8.</span> [<a href="/pubmed/1919691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1919691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.denier.2004a.326">Denier C, Goutagny S, Labauge P, Krivosic V, Arnoult M, Cousin A, Benabid AL, Comoy J, Frerebeau P, Gilbert B, Houtteville JP, Jan M, Lapierre F, Loiseau H, Menei P, Mercier P, Moreau JJ, Nivelon-Chevallier A, Parker F, Redondo AM, Scarabin JM, Tremoulet M, Zerah M, Maciazek J, Tournier-Lasserve E. Mutations within the MGC4607 gene cause cerebral cavernous malformations. <span><span class="ref-journal">Am J Hum Genet. </span>2004a;<span class="ref-vol">74</span>:326–37.</span> [<a href="/pmc/articles/PMC1181930/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1181930</span></a>] [<a href="/pubmed/14740320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14740320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.denier.2006.550">Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnoult M, Maciazek J, Vicaut E, Brunereau L, Tournier-Lasserve E. Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Neurochirurgie. Genotype-phenotype correlations in cerebral cavernous malformations patients. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">60</span>:550–6.</span> [<a href="/pubmed/17041941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17041941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.denier.2004b.213">Denier C, Labauge P, Brunereau L, Cav&#x000e9;-Riant F, Marchelli F, Arnoult M, Cecillon M, Maciazek J, Joutel A, Tournier-Lasserve E. Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. <span><span class="ref-journal">Ann Neurol. </span>2004b;<span class="ref-vol">55</span>:213–20.</span> [<a href="/pubmed/14755725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14755725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.deutsch.2000.65">Deutsch H, Jallo GI, Faktorovich A, Epstein F. Spinal intramedullary cavernoma: clinical presentation and surgical outcome. <span><span class="ref-journal">J Neurosurg. </span>2000;<span class="ref-vol">93</span>:65–70.</span> [<a href="/pubmed/10879760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10879760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.distefano.2014.33054">DiStefano PV, Kuebel JM, Sarelius IH, Glading AJ. KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling. <span><span class="ref-journal">J Biol Chem. </span>2014;<span class="ref-vol">289</span>:33054–65.</span> [<a href="/pmc/articles/PMC4239650/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4239650</span></a>] [<a href="/pubmed/25320085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25320085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.dobyns.1987.578">Dobyns WB, Michels VV, Groover RV, Mokri B, Trautmann JC, Forbes GS, Laws ER Jr. Familial cavernous malformations of the central nervous system and retina. <span><span class="ref-journal">Ann Neurol. </span>1987;<span class="ref-vol">21</span>:578–83.</span> [<a href="/pubmed/3606045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3606045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.drigo.1994.205">Drigo P, Mammi I, Battistella PA, Ricchieri G, Carollo C. Familial cerebral, hepatic, and retinal cavernous angiomas: a new syndrome. <span><span class="ref-journal">Childs Nerv Syst. </span>1994;<span class="ref-vol">10</span>:205–9.</span> [<a href="/pubmed/7923228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7923228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.eerola.2000.1351">Eerola I, Plate KH, Spiegel R, Boon LM, Mulliken JB, Vikkula M. KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:1351–5.</span> [<a href="/pubmed/10814716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10814716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.erdur.2014.1846">Erdur H, Scheitz JF, T&#x000fc;t&#x000fc;nc&#x000fc; S, Fiebach JB, Endres M, Werring DJ, Nolte CH. Safety of thrombolysis in patients with acute ischemic stroke and cerebral cavernous malformations. <span><span class="ref-journal">Stroke. </span>2014;<span class="ref-vol">45</span>:1846–8.</span> [<a href="/pubmed/24788970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24788970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.fischer.2013.302">Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. <span><span class="ref-journal">Trends Mol Med. </span>2013;<span class="ref-vol">19</span>:302–8.</span> [<a href="/pubmed/23506982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23506982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.fisher.2015.7937">Fisher OS, Deng H, Liu D, Zhang Y, Wei R, Deng Y, Zhang F, Louvi A, Turk BE, Boggon TJ, Su B. Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex. <span><span class="ref-journal">Nat Commun. </span>2015;<span class="ref-vol">6</span>:7937.</span> [<a href="/pmc/articles/PMC4526114/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4526114</span></a>] [<a href="/pubmed/26235885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26235885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.flemming.2013.43">Flemming KD, Link MJ, Christianson TJ, Brown RD Jr. Use of antithrombotic agents in patients with intracerebral cavernous malformations. <span><span class="ref-journal">J Neurosurg. </span>2013;<span class="ref-vol">118</span>:43–6.</span> [<a href="/pubmed/22998055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22998055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.folkersma.2001.67">Folkersma H, Mooij JJ. Follow-up of 13 patients with surgical treatment of cerebral cavernous malformations: effect on epilepsy and patient disability. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2001;<span class="ref-vol">103</span>:67–71.</span> [<a href="/pubmed/11516547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11516547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.fritschi.1994.35">Fritschi JA, Reulen HJ, Spetzler RF, Zabramski JM. Cavernous malformations of the brain stem. A review of 139 cases. <span><span class="ref-journal">Acta Neurochir (Wien). </span>1994;<span class="ref-vol">130</span>:35–46.</span> [<a href="/pubmed/7725941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7725941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.gallione.2011.662">Gallione CJ, Solatycki A, Awad IA, Weber JL, Marchuk DA. A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations. <span><span class="ref-journal">Genet Med. </span>2011 Jul;<span class="ref-vol">13</span>(7):662–6.</span> [<a href="/pmc/articles/PMC3132303/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3132303</span></a>] [<a href="/pubmed/21543988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21543988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.gault.2006.1278">Gault J, Sain S, Hu LJ, Awad IA. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. <span><span class="ref-journal">Neurosurgery. </span>2006;<span class="ref-vol">59</span>:1278–84.</span> [<a href="/pubmed/17277691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17277691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.glading.2007.247">Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. <span><span class="ref-journal">J Cell Biol. </span>2007;<span class="ref-vol">179</span>:247–54.</span> [<a href="/pmc/articles/PMC2064761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2064761</span></a>] [<a href="/pubmed/17954608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17954608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.goitre.2010.e11786">Goitre L, Balzac F, Degani S, Degan P, Marchi S, Pinton P, Retta SF. KRIT1 regulates the homeostasis of intracellular reactive oxygen species. <span><span class="ref-journal">PLoS One. </span>2010;<span class="ref-vol">5</span>:e11786.</span> [<a href="/pmc/articles/PMC2910502/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2910502</span></a>] [<a href="/pubmed/20668652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20668652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.goitre.2014.134">Goitre L, De Luca E, Braggion S, Trapani E, Guglielmotto M, Biasi F, Forni M, Moglia A, Trabalzini L, Retta SF. KRIT1 loss of function causes a ROS-dependent upregulation of c-Jun. <span><span class="ref-journal">Free Radic Biol Med. </span>2014;<span class="ref-vol">68</span>:134–47.</span> [<a href="/pmc/articles/PMC3994518/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3994518</span></a>] [<a href="/pubmed/24291398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24291398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.golden.2015.134">Golden M, Saeidi S, Liem B, Marchand E, Morrison L, Hart B. Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. <span><span class="ref-journal">J Med Imaging Radiat Oncol. </span>2015;<span class="ref-vol">59</span>:134–6.</span> [<a href="/pmc/articles/PMC4437719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4437719</span></a>] [<a href="/pubmed/25565562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25565562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.guarnieri.2007.29">Guarnieri V, Muscarella LA, Amoroso R, Quattrone A, Abate ME, Coco M, Catapano D, D'Angelo VA, Zelante L, D'Agruma L. Identification of two novel mutations and of a novel critical region in the KRIT1 gene. <span><span class="ref-journal">Neurogenetics. </span>2007;<span class="ref-vol">8</span>:29–37.</span> [<a href="/pubmed/17043900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17043900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.gianfrancesco.2007.691">Gianfrancesco F, Cannella M, Martino T, Maglione V, Esposito T, Innocenzi G, Vitale E, Liquori CL, Marchuk DA, Squitieri F. Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2007;<span class="ref-vol">144B</span>:691–5.</span> [<a href="/pubmed/17440989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17440989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.gibson.2015.289">Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, Shiu YT, Grossmann AH, Thomas KR, Donato AJ, Lesniewski LA, Whitehead KJ, Li DY. Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. <span><span class="ref-journal">Circulation. </span>2015;<span class="ref-vol">131</span>:289–99.</span> [<a href="/pmc/articles/PMC4356181/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4356181</span></a>] [<a href="/pubmed/25486933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25486933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.gunel.1996.946">Gunel M, Awad IA, Finberg K, Anson JA, Steinberg GK, Batjer HH, Kopitnik TA, Morrison L, Giannotta SL, Nelson-Williams C, Lifton RP. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">334</span>:946–51.</span> [<a href="/pubmed/8596595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8596595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.guclu.2005.1008">Guclu B, Ozturk AK, Pricola KL, Bilguvar K, Shin D, O'Roak BJ, Gunel M. Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3. <span><span class="ref-journal">Neurosurgery. </span>2005;<span class="ref-vol">57</span>:1008–13.</span> [<a href="/pubmed/16284570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16284570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.he.2010.ra26">He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H, Min W. Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. <span><span class="ref-journal">Sci Signal. </span>2010;<span class="ref-vol">3</span>:ra26.</span> [<a href="/pmc/articles/PMC3052863/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3052863</span></a>] [<a href="/pubmed/20371769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20371769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.heros.2000">Heros RC, Heros DO. Principles of neurosurgery. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. <em>Neurology in Clinical Practice</em>. Vol 1. Boston, MA: Butterworth Heinemann; 2000:931-58.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.hilder.2007.4343">Hilder TL, Malone MH, Bencharit S, Colicelli J, Haystead TA, Johnson GL, Wu CC. Proteomic identification of the cerebral cavernous malformation signaling complex. <span><span class="ref-journal">J Proteome Res. </span>2007;<span class="ref-vol">6</span>:4343–55.</span> [<a href="/pubmed/17900104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17900104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.horowitz.1995.1353">Horowitz M, Kondziolka D. Multiple familial cavernous malformations evaluated over three generations with MR. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>1995;<span class="ref-vol">16</span>:1353–5.</span> [<a href="/pubmed/7677039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7677039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.johnson.1995.368">Johnson EW, Iyer LM, Rich SS, Orr HT, Gil-Nagel A, Kurth JH, Zabramski JM, Marchuk DA, Weissenbach J, Clericuzio CL, Davis LE, Hart BL, Gusella JF, Kosofsky BE, Louis DN, Morrison LA, Green ED, Weber JL. Refined localization of the cerebral cavernous malformation gene (CCM1) to a 4-cM interval of chromosome 7q contained in a well-defined YAC contig. <span><span class="ref-journal">Genome Res. </span>1995;<span class="ref-vol">5</span>:368–80.</span> [<a href="/pubmed/8750196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8750196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.johnson.2004">Johnson EW, Marchuk DA, Zabramski JM. Genetics of cerebral cavernous malformations. In: Winn HR, ed. <em>Youman's Neurological Surgery</em>. 5 ed. Vol 2. Philadelphia, PA: WB Saunders Co, Philadelphia; 2004:2299-304.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.kalani.2013.50">Kalani MY, Zabramski JM. Risk for symptomatic hemorrhage of cerebral cavernous malformations during pregnancy. <span><span class="ref-journal">J Neurosurg. </span>2013;<span class="ref-vol">118</span>:50–5.</span> [<a href="/pubmed/23039155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23039155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.kida.2015.s249">Kida Y, Hasegawa T, Iwai Y, Shuto T, Satoh M, Kondoh T, Hayashi M. Radiosurgery for symptomatic cavernous malformations: A multi-institutional retrospective study in Japan. <span><span class="ref-journal">Surg Neurol Int. </span>2015;<span class="ref-vol">6</span>:S249–57.</span> [<a href="/pmc/articles/PMC4434491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4434491</span></a>] [<a href="/pubmed/26005588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26005588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.kuhn.2009.154">Kuhn J, Br&#x000fc;mmendorf TH, Brassat U, Lehnhardt FG, Chung BD, Harnier S, Bewermeyer H, Harzheim A, Assheuer J, Netzer C. Novel KRIT1 mutation and no molecular evidence of anticipation in a family with cerebral and spinal cavernous malformations. <span><span class="ref-journal">Eur Neurol. </span>2009;<span class="ref-vol">61</span>:154–8.</span> [<a href="/pubmed/19092252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19092252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.kurlemann.2012.513">Kurlemann G. Neurocutaneous syndromes. <span><span class="ref-journal">Handb Clin Neurol. </span>2012;<span class="ref-vol">108</span>:513–33.</span> [<a href="/pubmed/22939051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22939051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.labauge.2001.1825">Labauge P, Brunereau L, Laberge S, Houtteville JP. Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:1825–8.</span> [<a href="/pubmed/11723271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11723271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.labauge.1999.250">Labauge P, Enjolras O, Bonerandi JJ, Laberge S, Dandurand M, Joujoux JM, Tournier-Lasserve E. An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">45</span>:250–4.</span> [<a href="/pubmed/9989629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9989629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.labauge.2006.885">Labauge P, Krivosic V, Denier C, Tournier-Lasserve E, Gaudric A. Frequency of retinal cavernomas in 60 patients with familial cerebral cavernomas: a clinical and genetic study. <span><span class="ref-journal">Arch Ophthalmol. </span>2006;<span class="ref-vol">124</span>:885–6.</span> [<a href="/pubmed/16769843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.lanfranconi.2014.158">Lanfranconi S, Ronchi D, Ahmed N, Civelli V, Basilico P, Bresolin N, Comi GP, Corti S. A novel CCM1 mutation associated with multiple cerebral and vertebral cavernous malformations. <span><span class="ref-journal">BMC Neurol. </span>2014;<span class="ref-vol">14</span>:158.</span> [<a href="/pmc/articles/PMC4236643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4236643</span></a>] [<a href="/pubmed/25086949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25086949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.larson.1998.51">Larson JJ, Ball WS, Bove KE, Crone KR, Tew JM Jr. Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. <span><span class="ref-journal">J Neurosurg. </span>1998;<span class="ref-vol">88</span>:51–6.</span> [<a href="/pubmed/9420072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9420072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.lee.2008.321">Lee JW, Kim DS, Shim KW, Chang JH, Huh SK, Park YG, Choi JU. Management of intracranial cavernous malformation in pediatric patients. <span><span class="ref-journal">Childs Nerv Syst. </span>2008;<span class="ref-vol">24</span>:321–7.</span> [<a href="/pubmed/17876588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17876588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.liquori.2007.69">Liquori CL, Berg MJ, Squitieri F, Leedom TP, Ptacek L, Johnson EW, Marchuk DA. Deletions in CCM2 are a common cause of cerebral cavernous malformations. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">80</span>:69–75.</span> [<a href="/pmc/articles/PMC1785317/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1785317</span></a>] [<a href="/pubmed/17160895" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17160895</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.liquori.2006.118">Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, Sorlie M, Leedom TP, Cannella M, Maglione V, Ptacek L, Johnson EW, Marchuk DA. Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:118.</span> [<a href="/pubmed/16329096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16329096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.liquori.2008.25">Liquori CL, Penco S, Gault J, Leedom TP, Tassi L, Esposito T, Awad IA, Frati L, Johnson EW, Squitieri F, Marchuk DA, Gianfrancesco F. Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. <span><span class="ref-journal">Neurogenetics. </span>2008;<span class="ref-vol">9</span>:25–31.</span> [<a href="/pubmed/18060436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18060436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.lucas.2001.529">Lucas M, Costa AF, Montori M, Solano F, Zayas MD, Izquierdo G. Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:529–32.</span> [<a href="/pubmed/11310633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11310633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.macek_jilkova.2014.1228">Macek Jilkova Z, Lisowska J, Manet S, Verdier C, Deplano V, Geindreau C, Faurobert E, Albig&#x000e8;s-Rizo C, Duperray A. CCM proteins control endothelial &#x003b2;1 integrin dependent response to shear stress. <span><span class="ref-journal">Biol Open. </span>2014;<span class="ref-vol">3</span>:1228–35.</span> [<a href="/pmc/articles/PMC4265761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4265761</span></a>] [<a href="/pubmed/25432514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25432514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.maddaluno.2013.492">Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday G, Tournier-Lasserve E, Chapon F, Richichi C, Retta SF, Lampugnani MG, Dejana E. EndMT contributes to the onset and progression of cerebral cavernous malformations. <span><span class="ref-journal">Nature. </span>2013;<span class="ref-vol">498</span>:492–6.</span> [<a href="/pubmed/23748444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23748444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.marchi.2015.1403">Marchi S, Corricelli M, Trapani E, Bravi L, Pittaro A, Delle Monache S, Ferroni L, Patergnani S, Missiroli S, Goitre L, Trabalzini L, Rimessi A, Giorgi C, Zavan B, Cassoni P, Dejana E, Retta SF, Pinton P. Defective autophagy is a key feature of cerebral cavernous malformations. <span><span class="ref-journal">EMBO Mol Med. </span>2015;<span class="ref-vol">7</span>:1403–17.</span> [<a href="/pmc/articles/PMC4644374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4644374</span></a>] [<a href="/pubmed/26417067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26417067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.mcdonald.2012.571">McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH, Marchuk DA, Awad IA. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. <span><span class="ref-journal">Stroke. </span>2012;2012;<span class="ref-vol">43</span>:571–4.</span> [<a href="/pmc/articles/PMC3265629/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3265629</span></a>] [<a href="/pubmed/22034008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22034008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.mohr.2005">Mohr JP, Pile-Spellman J. Vascular tumor and malformations. In: Rowland LP, ed. <em>Merritt's Neurology</em>. 11 ed. Philadelphia, PA: Lippincott Williams &#x00026; Wilkins; 2005:449-59.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.monaco.2010.e11">Monaco EA, Khan AA, Niranjan A, Kano H, Grandhi R, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for the treatment of symptomatic brainstem cavernous malformations. <span><span class="ref-journal">Neurosurg Focus. </span>2010;<span class="ref-vol">29</span>:E11.</span> [<a href="/pubmed/20809752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20809752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.moultrie.2014.582">Moultrie F, Horne MA, Josephson CB, Hall JM, Counsell CE, Bhattacharya JJ, Papanastassiou V, Sellar RJ, Warlow CP, Murray GD, Al-Shahi Salman R. Scottish Audit of Intracranial Vascular Malformations (SAIVMs) steering committee and collaborators. Outcome after surgical or conservative management of cerebral cavernous malformations. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:582–9.</span> [<a href="/pmc/articles/PMC4141991/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4141991</span></a>] [<a href="/pubmed/24994841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24994841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.nikoubashman.2015.2177">Nikoubashman O, Di Rocco F, Davagnanam I, Mankad K, Zerah M, Wiesmann M. Prospective Hemorrhage Rates of Cerebral Cavernous Malformations in Children and Adolescents Based on MRI Appearance. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2015;<span class="ref-vol">36</span>:2177–83.</span> [<a href="/pubmed/26272978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26272978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.nikoubashman.2013.e453">Nikoubashman O, Wiesmann M, Tournier-Lasserve E, Mankad K, Bourgeois M, Brunelle F, Sainte-Rose C, Wiesmann M, Zerah M, Di Rocco F. Natural history of cerebral dot-like cavernomas. <span><span class="ref-journal">Clin Radiol. </span>2013;<span class="ref-vol">68</span>:e453–9.</span> [<a href="/pubmed/23663874" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23663874</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.nimjee.2006.e4">Nimjee SM, Powers CJ, Bulsara KR. Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. <span><span class="ref-journal">Neurosurg Focus. </span>2006;<span class="ref-vol">21</span>:e4.</span> [<a href="/pubmed/16859257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16859257</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.otten.1989.82">Otten P, Pizzolato GP, Rilliet B, Berney J. 131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies. <span><span class="ref-journal">Neurochirurgie. </span>1989;<span class="ref-vol">35</span>:82–3, 128-31.</span> [<a href="/pubmed/2674753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2674753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.pagenstecher.2009.911">Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:911–8.</span> [<a href="/pmc/articles/PMC2640205/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640205</span></a>] [<a href="/pubmed/19088124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19088124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.palma.2009.e83">Palma JA, Zubieta JL, Dominguez PD, Garcia-Eulate R. Pneumocephalus mimicking cerebral cavernous malformations in MR susceptibility-weighted imaging. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2009;<span class="ref-vol">30</span>:e83.</span> [<a href="/pubmed/19342538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19342538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.petersen.2010.377">Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2010;<span class="ref-vol">31</span>:377–82.</span> [<a href="/pmc/articles/PMC4455949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4455949</span></a>] [<a href="/pubmed/19833796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19833796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.revencu.2006.716">Revencu N, Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:716–21.</span> [<a href="/pmc/articles/PMC2564569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564569</span></a>] [<a href="/pubmed/16571644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16571644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.riant.2010.1070">Riant F, Bergametti F, Ayrignac X, Boulday G, Tournier-Lasserve E. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. <span><span class="ref-journal">FEBS J. </span>2010;<span class="ref-vol">277</span>:1070–5.</span> [<a href="/pubmed/20096038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20096038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.riant.2013.165">Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M, Lejeune P, Hosseini H, Choe C, Orth M, Bernreuther C, Boulday G, Denier C, Labauge P, Tournier-Lasserve E. CCM3 Mutations Are Associated with Early-Onset Cerebral Hemorrhage and Multiple Meningiomas. <span><span class="ref-journal">Mol Syndromol. </span>2013;2013;<span class="ref-vol">4</span>:165–72.</span> [<a href="/pmc/articles/PMC3666455/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3666455</span></a>] [<a href="/pubmed/23801932" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23801932</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.rigamonti.1987.518">Rigamonti D, Drayer BP, Johnson PC, Hadley MN, Zabramski J, Spetzler RF. The MRI appearance of cavernous malformations (angiomas). <span><span class="ref-journal">J Neurosurg. </span>1987;<span class="ref-vol">67</span>:518–24.</span> [<a href="/pubmed/3655889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3655889</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.rigamonti.1988.343">Rigamonti D, Hadley MN, Drayer BP, Johnson PC, Hoenig-Rigamonti K, Knight JT, Spetzler RF. Cerebral cavernous malformations. Incidence and familial occurrence. <span><span class="ref-journal">N Engl J Med. </span>1988;<span class="ref-vol">319</span>:343–7.</span> [<a href="/pubmed/3393196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3393196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.robinson.1991.709">Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. <span><span class="ref-journal">J Neurosurg. </span>1991;<span class="ref-vol">75</span>:709–14.</span> [<a href="/pubmed/1919692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1919692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.sahoo.1999.2325">Sahoo T, Johnson EW, Thomas JW, Kuehl PM, Jones TL, Dokken CG, Touchman JW, Gallione CJ, Lee-Lin SQ, Kosofsky B, Kurth JH, Louis DN, Mettler G, Morrison L, Gil-Nagel A, Rich SS, Zabramski JM, Boguski MS, Green ED, Marchuk DA. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:2325–33.</span> [<a href="/pubmed/10545614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10545614</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.sarma.2016.467">Sarma AK, Khandker N, Kurczewski L, Brophy GM. Medical management of epileptic seizures: challenges and solutions. <span><span class="ref-journal">Neuropsychiatr Dis Treat. </span>2016;<span class="ref-vol">12</span>:467–85.</span> [<a href="/pmc/articles/PMC4771397/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4771397</span></a>] [<a href="/pubmed/26966367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26966367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.sarraf.2000.969">Sarraf D, Payne AM, Kitchen ND, Sehmi KS, Downes SM, Bird AC. Familial cavernous hemangioma: An expanding ocular spectrum. <span><span class="ref-journal">Arch Ophthalmol. </span>2000;<span class="ref-vol">118</span>:969–73.</span> [<a href="/pubmed/10900112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10900112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.schneble.2012.3196">Schneble HM, Sounmare A, Herve D, Bresson D, Guichard JP, Riant F, Tournier-Lasserve E, Tzourio C, Chabriat H, Stapf C. Antithrombotic therapy and bleeding risk in a prespective cohort study of patients with cerebral cavernous malformations. <span><span class="ref-journal">Stroke. </span>2012;<span class="ref-vol">43</span>:3196–9.</span> [<a href="/pubmed/23150651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23150651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.selman.2000">Selman WR, Tarr RW, Ratcheson RA. Arteriovenous malformation. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. <em>Neurology in Clinical Practice</em>. Vol 1. Boston, MA: Butterworth Heinemann; 2000:1201-14.</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.sharma.2011.110.e1">Sharma S, Tsyvine D, Maldjian PD, Sambol JT, Lovoulos CJ, Levy G, Maghari A, Klapholz M, Saric M. An intriguing co-existence: atrial myxoma and cerebral cavernous malformations: case report and review of literature. <span><span class="ref-journal">J Am Soc Echocardiogr. </span>2011;<span class="ref-vol">24</span>:110.e1–4.</span> [<a href="/pubmed/20650606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20650606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.shenkar.2015.188">Shenkar R, Shi C, Rebeiz T, Stockton RA, McDonald DA, Mikati AG, Zhang L, Austin C, Akers AL, Gallione CJ, Rorrer A, Gunel M, Min W, Marcondes de Souza J, Lee C, Marchuk DA, Awad IA. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. <span><span class="ref-journal">Genet Med. </span>2015;<span class="ref-vol">17</span>:188–96.</span> [<a href="/pmc/articles/PMC4329119/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4329119</span></a>] [<a href="/pubmed/25122144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25122144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.simonazzi.2014.261">Simonazzi G, Curti A, Rapacchia G, Gabrielli S, Pilu G, Rizzo N, Pozzati E. Symptomatic cerebral cavernomas in pregnancy: a series of 6 cases and review of the literature. <span><span class="ref-journal">J Matern Fetal Neonatal Med. </span>2014;<span class="ref-vol">27</span>:261–4.</span> [<a href="/pubmed/23718734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23718734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.sirvente.2009.1066">Sirvente J, Enjolras O, Wassef M, Tournier-Lasserve E, Labauge P. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. <span><span class="ref-journal">J Eur Acad Dermatol Venereol. </span>2009;<span class="ref-vol">23</span>:1066–72.</span> [<a href="/pubmed/19453802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19453802</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.spencer.1984.432">Spencer DD, Spencer SS, Mattson RH, Williamson PD. Intracerebral masses in patients with intractable partial epilepsy. <span><span class="ref-journal">Neurology. </span>1984;<span class="ref-vol">34</span>:432–6.</span> [<a href="/pubmed/6422323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6422323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.spiegler.2014.176">Spiegler S, Najm J, Liu J, Gkalympoudis S, Schr&#x000f6;der W, Borck G, Brockmann K, Elbracht M, Fauth C, Ferbert A, Freudenberg L, Grasshoff U, Hellenbroich Y, Henn W, Hoffjan S, H&#x000fc;ning I, Korenke GC, Kroisel PM, Kunstmann E, Mair M, Munk-Schulenburg S, Nikoubashman O, Pauli S, Rudnik-Sch&#x000f6;neborn S, Sudholt I, Sure U, Tinschert S, Wiednig M, Zoll B, Ginsberg MH, Felbor U. High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2014;<span class="ref-vol">2</span>:176–85.</span> [<a href="/pmc/articles/PMC3960060/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3960060</span></a>] [<a href="/pubmed/24689081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24689081</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.stahl.2008.709">Stahl S, Gaetzner S, Voss K, Brackertz B, Schleider E, S&#x000fc;r&#x000fc;c&#x000fc; O, Kunze E, Netzer C, Korenke C, Finckh U, Habek M, Poljakovic Z, Elbracht M, Rudnik-Sch&#x000f6;neborn S, Bertalanffy H, Sure U, Felbor U. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:709–17.</span> [<a href="/pubmed/18300272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18300272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.steiner.2010.16">Steiner L, Karlsson B, Yen CP, Torner JC, Lindquist C, Schlesinger D. Radiosurgery in cavernous malformations: anatomy of a controversy. <span><span class="ref-journal">J Neurosurg. </span>2010;<span class="ref-vol">113</span>:16–21.</span> [<a href="/pubmed/20170301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20170301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.stockton.2010.881">Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. <span><span class="ref-journal">J Exp Med. </span>2010;<span class="ref-vol">207</span>:881–96.</span> [<a href="/pmc/articles/PMC2856024/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2856024</span></a>] [<a href="/pubmed/20308363" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20308363</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.toldo.2009.167">Toldo I, Drigo P, Mammi I, Marini V, Carollo C. Vertebral and spinal cavernous angiomas associated with familial cerebral cavernous malformation. <span><span class="ref-journal">Surg Neurol. </span>2009;<span class="ref-vol">71</span>:167–71.</span> [<a href="/pubmed/18207546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18207546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.uhlik.2003.1104">Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, Horne EA, Dell'Acqua ML, Johnson GL. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. <span><span class="ref-journal">Nat Cell Biol. </span>2003;<span class="ref-vol">5</span>:1104–10.</span> [<a href="/pubmed/14634666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14634666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.verlaan.2002a.853">Verlaan DJ, Davenport WJ, Stefan H, Sure U, Siegel AM, Rouleau GA. Cerebral cavernous malformations: Mutations in Krit1. <span><span class="ref-journal">Neurology. </span>2002a;<span class="ref-vol">58</span>:853–7.</span> [<a href="/pubmed/11914398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11914398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.verlaan.2002b.1564">Verlaan DJ, Siegel AM, Rouleau GA. Krit1 missense mutations lead to splicing errors in cerebral caverno us malformation. <span><span class="ref-journal">Am J Hum Genet. </span>2002b;<span class="ref-vol">70</span>:1564–7.</span> [<a href="/pmc/articles/PMC379143/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379143</span></a>] [<a href="/pubmed/11941540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11941540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.voss.2007.249">Voss K, Stahl S, Schleider E, Ullrich S, Nickel J, Mueller TD, Felbor U. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. <span><span class="ref-journal">Neurogenetics. </span>2007;<span class="ref-vol">8</span>:249–56.</span> [<a href="/pubmed/17657516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17657516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.wang.2010.474">Wang P, Zhang F, Zhang H, Zhao H. Gamma knife radiosurgery for intracranial cavernous malformations. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2010;<span class="ref-vol">112</span>:474–7.</span> [<a href="/pubmed/20371149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20371149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.wang.1999.323">Wang Y, Liu H, Zhang Y, Ma D. cDNA cloning and expression of an apoptosis-related gene, humanTFAR15 gene. <span><span class="ref-journal">Sci China C Life Sci. </span>1999;<span class="ref-vol">42</span>:323–9.</span> [<a href="/pubmed/20229348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20229348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.whitehead.2009.177">Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, Mayo AH, Drakos SG, Jones CA, Zhu W, Marchuk DA, Davis GE, Li DY. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. <span><span class="ref-journal">Nat Med. </span>2009;<span class="ref-vol">15</span>:177–84.</span> [<a href="/pmc/articles/PMC2767168/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2767168</span></a>] [<a href="/pubmed/19151728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19151728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.witiw.2012.626">Witiw CD, Abou-Hamden A, Kulkarni AV, Silvaggio JA, Schneider C, Wallace MC. Cerebral cavernous malformations and pregnancy: hemorrhage risk and influence on obstetrical management. <span><span class="ref-journal">Neurosurgery. </span>2012;<span class="ref-vol">71</span>:626–30.</span> [<a href="/pubmed/22710379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22710379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.wood.1957.249">Wood MW, White RJ, Kernohan JW. Cavernous hemangiomatosis involving the brain, spinal cord, heart, skin and kidney: report of case. <span><span class="ref-journal">Proc Staff Meet Mayo Clin. </span>1957;<span class="ref-vol">32</span>:249–54.</span> [<a href="/pubmed/13441756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13441756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.w_stehube.2010.12640">W&#x000fc;stehube J, Bartol A, Liebler SS, Br&#x000fc;tsch R, Zhu Y, Felbor U, Sure U, Augustin HG, Fischer A. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2010;<span class="ref-vol">107</span>:12640–5.</span> [<a href="/pmc/articles/PMC2906569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2906569</span></a>] [<a href="/pubmed/20616044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20616044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.yamada.2013.555">Yamada S, Nakase H, Nakagawa I, Nishimura F, Motoyama Y, Park YS. Cavernous malformations in pregnancy. <span><span class="ref-journal">Neurol Med Chir (Tokyo). </span>2013;<span class="ref-vol">53</span>:555–60.</span> [<a href="/pubmed/23979052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23979052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.you.2013.407">You C, Sandalcioglu IE, Dammann P, Felbor U, Sure U, Zhu Y. Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. <span><span class="ref-journal">J Cell Mol Med. </span>2013;2013;<span class="ref-vol">17</span>:407–18.</span> [<a href="/pmc/articles/PMC3823022/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3823022</span></a>] [<a href="/pubmed/23388056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23388056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.zabramski.1994.422">Zabramski JM, Wascher TM, Spetzler RF, Johnson B, Golfinos J, Drayer BP, Brown B, Rigamonti D, Brown G. The natural history of familial cavernous malformations: results of an ongoing study. <span><span class="ref-journal">J Neurosurg. </span>1994;<span class="ref-vol">80</span>:422–32.</span> [<a href="/pubmed/8113854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8113854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.zawistowski.2002.389">Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:389–96.</span> [<a href="/pubmed/11854171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11854171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ccm.REF.zlotoff.2007.210">Zlotoff BJ, Bang RH, Padilla RS, Morrison L. Cutaneous angiokeratoma and venous malformations in a Hispanic-American patient with cerebral cavernous malformations. <span><span class="ref-journal">Br J Dermatol. </span>2007;<span class="ref-vol">157</span>:210–2.</span> [<a href="/pubmed/17578448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17578448</span></a>]</div></li></ul></div></div><div id="ccm.Chapter_Notes"><h2 id="_ccm_Chapter_Notes_">Chapter Notes</h2><div id="ccm.Author_Notes"><h3>Author Notes</h3><p>NIH Funding- 454RD</p><p>Scientific Advisory Board, Angioma Alliance</p></div><div id="ccm.Author_History"><h3>Author History</h3><p>Amy Akers, PhD (2011-present)<br />Leslie Morrison, MD (2011-present)<br />Eric W Johnson, PhD; Barrow Neurological Institute (2003-2011)</p></div><div id="ccm.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>4 August 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 May 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 July 2006 (ej) Revision: additional information on CCM4; prenatal testing available for <i>KRIT1</i>, <i>CCM2</i>, and <i>PDCD10</i></div></li><li class="half_rhythm"><div>31 May 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 September 2004 (ej) Revision: change in testing</div></li><li class="half_rhythm"><div>18 March 2004 (ej) Revision: identification of <i>CCM2</i></div></li><li class="half_rhythm"><div>24 February 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>5 February 2002 (ej) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1293</span><span class="label">PMID: <a href="/pubmed/20301470" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301470</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cco/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ctx/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1293&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1293/?report=reader">PubReader</a></li><li><a href="/books/NBK1293/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1293" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1293" style="display:none" title="Cite this Page"><div class="bk_tt">Morrison L, Akers A. Cerebral Cavernous Malformation, Familial. 2003 Feb 24 [Updated 2016 Aug 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1293/pdf/Bookshelf_NBK1293.pdf">PDF version of this page</a> (546K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ccm.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ccm.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ccm.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ccm.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ccm.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ccm.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ccm.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ccm.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ccm.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ccm.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ccm.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=11235[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PDCD10</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=83605[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CCM2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=889[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRIT1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1464662" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1464662" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1464662" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1464662" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30151459" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Familial Multiple Cavernous Malformation Syndrome: MR Features in This Uncommon but Silent Threat.</a><span class="source">[J Belg Soc Radiol. 2016]</span><div class="brieflinkpop offscreen_noflow">Familial Multiple Cavernous Malformation Syndrome: MR Features in This Uncommon but Silent Threat.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mespreuve M, Vanhoenacker F, Lemmerling M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Belg Soc Radiol. 2016 Mar 21; 100(1):51. Epub 2016 Mar 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27708576" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A Novel &lt;i&gt;CCM2&lt;/i&gt; Gene Mutation Associated with Familial Cerebral Cavernous Malformation.</a><span class="source">[Front Aging Neurosci. 2016]</span><div class="brieflinkpop offscreen_noflow">A Novel &lt;i&gt;CCM2&lt;/i&gt; Gene Mutation Associated with Familial Cerebral Cavernous Malformation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Huang WQ, Lu CX, Zhang Y, Yi KH, Cai LL, Li ML, Wang H, Lin Q, Tzeng CM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Front Aging Neurosci. 2016; 8:220. Epub 2016 Sep 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28160210" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A Novel KRIT1/CCM1 Gene Insertion Mutation Associated with Cerebral Cavernous Malformations in a Chinese Family.</a><span class="source">[J Mol Neurosci. 2017]</span><div class="brieflinkpop offscreen_noflow">A Novel KRIT1/CCM1 Gene Insertion Mutation Associated with Cerebral Cavernous Malformations in a Chinese Family.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang H, Pan Y, Zhang Z, Li X, Xu Z, Suo Y, Li W, Wang Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Mol Neurosci. 2017 Feb; 61(2):221-226. Epub 2017 Feb 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30234941" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KCNT1</i>-Related Epilepsy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">KCNT1</i>-Related Epilepsy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gertler T, Bearden D, Bhattacharjee A, Carvill G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301470" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301470" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc890075f66d18aa9980bd">Cerebral Cavernous Malformation, Familial - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Cerebral Cavernous Malformation, Familial - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T03:40:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89283FDFC733A1000000000A540523&amp;ncbi_session=CE89283FDFC88FF1_2644SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1293%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1293&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1293/&amp;ncbi_pagename=Cerebral Cavernous Malformation, Familial - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89283FDFC88FF1_2644SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>